JP2008520702A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008520702A5 JP2008520702A5 JP2007543263A JP2007543263A JP2008520702A5 JP 2008520702 A5 JP2008520702 A5 JP 2008520702A5 JP 2007543263 A JP2007543263 A JP 2007543263A JP 2007543263 A JP2007543263 A JP 2007543263A JP 2008520702 A5 JP2008520702 A5 JP 2008520702A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- triazole
- mercapto
- phenyl
- dihydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 60
- -1 2,4-dihydroxy-phenyl Chemical group 0.000 claims 46
- 125000001072 heteroaryl group Chemical group 0.000 claims 27
- 150000003839 salts Chemical class 0.000 claims 27
- 239000000651 prodrug Substances 0.000 claims 26
- 229940002612 prodrug Drugs 0.000 claims 26
- 239000012453 solvate Substances 0.000 claims 26
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 21
- 125000003710 aryl alkyl group Chemical group 0.000 claims 20
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 20
- 125000000623 heterocyclic group Chemical group 0.000 claims 20
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 20
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 19
- 125000000547 substituted alkyl group Chemical group 0.000 claims 19
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 18
- 125000003107 substituted aryl group Chemical group 0.000 claims 18
- 125000003545 alkoxy group Chemical group 0.000 claims 15
- 125000001188 haloalkyl group Chemical group 0.000 claims 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims 14
- 125000001475 halogen functional group Chemical group 0.000 claims 14
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 13
- 125000004438 haloalkoxy group Chemical group 0.000 claims 9
- 125000004404 heteroalkyl group Chemical group 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000004414 alkyl thio group Chemical group 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- ZAVMYGRJGRTKNS-UHFFFAOYSA-N 4-(1,2-dimethylindol-5-yl)-3-(5-ethyl-2,4-dihydroxyphenyl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(CC)=CC(C=2N(C(S)=NN=2)C=2C=C3C=C(C)N(C)C3=CC=2)=C1O ZAVMYGRJGRTKNS-UHFFFAOYSA-N 0.000 claims 2
- FMRNAECAMZWTOH-UHFFFAOYSA-N 4-(1-ethylbenzimidazol-4-yl)-3-(5-ethyl-2,4-dihydroxyphenyl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(CC)=CC(C=2N(C(S)=NN=2)C=2C=3N=CN(CC)C=3C=CC=2)=C1O FMRNAECAMZWTOH-UHFFFAOYSA-N 0.000 claims 2
- RHAYKNNJVHVROS-UHFFFAOYSA-N 4-[5-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound OC1=CC(O)=CC=C1N1C(C=2C=3OCCOC=3C=CC=2)=C(S)N=N1 RHAYKNNJVHVROS-UHFFFAOYSA-N 0.000 claims 2
- QDVZGIRSUDZLCA-UHFFFAOYSA-N 4-[5-(2,6-dimethylphenyl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound CC1=CC=CC(C)=C1C1=C(S)N=NN1C1=CC=C(O)C=C1O QDVZGIRSUDZLCA-UHFFFAOYSA-N 0.000 claims 2
- GPNWYLMMEXOXCR-UHFFFAOYSA-N 4-[5-(5-methoxynaphthalen-1-yl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound C1=CC=C2C(OC)=CC=CC2=C1C1=C(S)N=NN1C1=CC=C(O)C=C1O GPNWYLMMEXOXCR-UHFFFAOYSA-N 0.000 claims 2
- PCWPLZYTBMDRLQ-UHFFFAOYSA-N 5-amino-2-(5-naphthalen-1-yl-4-sulfanyltriazol-1-yl)phenol Chemical compound OC1=CC(N)=CC=C1N1C(C=2C3=CC=CC=C3C=CC=2)=C(S)N=N1 PCWPLZYTBMDRLQ-UHFFFAOYSA-N 0.000 claims 2
- PJSPUHPGJHMUDP-UHFFFAOYSA-N 5-methoxy-2-(5-naphthalen-1-yl-4-sulfanyltriazol-1-yl)phenol Chemical compound OC1=CC(OC)=CC=C1N1C(C=2C3=CC=CC=C3C=CC=2)=C(S)N=N1 PJSPUHPGJHMUDP-UHFFFAOYSA-N 0.000 claims 2
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 claims 2
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- XJNHHOSTXIXKSG-UHFFFAOYSA-N n-[3-hydroxy-4-(5-naphthalen-1-yl-4-sulfanyltriazol-1-yl)phenyl]acetamide Chemical compound OC1=CC(NC(=O)C)=CC=C1N1C(C=2C3=CC=CC=C3C=CC=2)=C(S)N=N1 XJNHHOSTXIXKSG-UHFFFAOYSA-N 0.000 claims 2
- 230000017854 proteolysis Effects 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 claims 1
- SYTBMCIDAYQZAC-UHFFFAOYSA-N 1-(2,4-dihydroxy-5-methoxyphenyl)-4-(sulfamoylamino)-5-[3-(trifluoromethyl)phenyl]triazole Chemical compound C1=C(O)C(OC)=CC(N2C(=C(NS(N)(=O)=O)N=N2)C=2C=C(C=CC=2)C(F)(F)F)=C1O SYTBMCIDAYQZAC-UHFFFAOYSA-N 0.000 claims 1
- ZBQGGNRZZXNKRJ-UHFFFAOYSA-N 1-(2,4-dihydroxy-5-methoxyphenyl)-5-naphthalen-1-yl-4-(sulfamoylamino)triazole Chemical compound C1=C(O)C(OC)=CC(N2C(=C(NS(N)(=O)=O)N=N2)C=2C3=CC=CC=C3C=CC=2)=C1O ZBQGGNRZZXNKRJ-UHFFFAOYSA-N 0.000 claims 1
- FNIXUOSHBLGHJQ-UHFFFAOYSA-N 1-(2,4-dihydroxyphenyl)-5-phenyl-4-(sulfamoylamino)triazole Chemical compound NS(=O)(=O)NC=1N=NN(C=2C(=CC(O)=CC=2)O)C=1C1=CC=CC=C1 FNIXUOSHBLGHJQ-UHFFFAOYSA-N 0.000 claims 1
- RYQIKRMARWEKEE-UHFFFAOYSA-N 1-(2-hydroxy-5-propan-2-ylphenyl)-5-naphthalen-1-yltriazol-4-ol Chemical compound CC(C)C1=CC=C(O)C(N2C(=C(O)N=N2)C=2C3=CC=CC=C3C=CC=2)=C1 RYQIKRMARWEKEE-UHFFFAOYSA-N 0.000 claims 1
- XDVUMDGLIFBVKT-UHFFFAOYSA-N 1-(5-ethoxy-2-hydroxyphenyl)-5-naphthalen-1-yltriazol-4-ol Chemical compound CCOC1=CC=C(O)C(N2C(=C(O)N=N2)C=2C3=CC=CC=C3C=CC=2)=C1 XDVUMDGLIFBVKT-UHFFFAOYSA-N 0.000 claims 1
- PCKARBFVTAHKLL-UHFFFAOYSA-N 1-[5-[3-(5-ethyl-2,4-dihydroxyphenyl)-5-sulfanylidene-1H-1,2,4-triazol-4-yl]-2,3-dimethylindol-1-yl]ethanone Chemical compound C1=C(O)C(CC)=CC(C=2N(C(S)=NN=2)C=2C=C3C(C)=C(C)N(C(C)=O)C3=CC=2)=C1O PCKARBFVTAHKLL-UHFFFAOYSA-N 0.000 claims 1
- CDZAJNIMEUBWQV-UHFFFAOYSA-N 1-ethyl-3-(5-naphthalen-1-yl-4-sulfanyltriazol-1-yl)-2h-pyridine-4,6-diol Chemical compound C1=C(O)N(CC)CC(N2C(=C(S)N=N2)C=2C3=CC=CC=C3C=CC=2)=C1O CDZAJNIMEUBWQV-UHFFFAOYSA-N 0.000 claims 1
- OJGHDSTXSCTGQW-UHFFFAOYSA-N 1-methyl-3-(5-naphthalen-1-yl-4-sulfanyltriazol-1-yl)-2h-pyridine-4,6-diol Chemical compound C1=C(O)N(C)CC(N2C(=C(S)N=N2)C=2C3=CC=CC=C3C=CC=2)=C1O OJGHDSTXSCTGQW-UHFFFAOYSA-N 0.000 claims 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical class C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 claims 1
- FBZZGYMSYBBAKH-UHFFFAOYSA-N 2-(5-naphthalen-1-yl-4-sulfanyltriazol-1-yl)phenol Chemical compound OC1=CC=CC=C1N1C(C=2C3=CC=CC=C3C=CC=2)=C(S)N=N1 FBZZGYMSYBBAKH-UHFFFAOYSA-N 0.000 claims 1
- GXECTKAVRLKCRG-UHFFFAOYSA-N 2-(hydroxymethyl)-5-(5-naphthalen-1-yl-4-sulfanyltriazol-1-yl)benzene-1,4-diol Chemical compound C1=C(O)C(CO)=CC(O)=C1N1C(C=2C3=CC=CC=C3C=CC=2)=C(S)N=N1 GXECTKAVRLKCRG-UHFFFAOYSA-N 0.000 claims 1
- BRGRHLDKJMLGSH-UHFFFAOYSA-N 2-[8-[3-(5-ethyl-2,4-dihydroxyphenyl)-5-sulfanyltriazol-4-yl]naphthalen-2-yl]oxyacetic acid Chemical compound C1=C(O)C(CC)=CC(N2C(=C(S)N=N2)C=2C3=CC(OCC(O)=O)=CC=C3C=CC=2)=C1O BRGRHLDKJMLGSH-UHFFFAOYSA-N 0.000 claims 1
- VODMUHBBWURJBK-UHFFFAOYSA-N 2-chloro-4-(5-naphthalen-1-yl-4-sulfanyltriazol-1-yl)benzene-1,3-diol Chemical compound OC1=C(Cl)C(O)=CC=C1N1C(C=2C3=CC=CC=C3C=CC=2)=C(S)N=N1 VODMUHBBWURJBK-UHFFFAOYSA-N 0.000 claims 1
- DMERZNBHHPJRBH-UHFFFAOYSA-N 2-chloro-4-ethyl-6-(5-naphthalen-1-yl-4-sulfanyltriazol-1-yl)benzene-1,3-diol Chemical compound ClC1=C(O)C(CC)=CC(N2C(=C(S)N=N2)C=2C3=CC=CC=C3C=CC=2)=C1O DMERZNBHHPJRBH-UHFFFAOYSA-N 0.000 claims 1
- MXKIFFBZWXCSSS-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-(1,3-dimethylindol-5-yl)-1H-1,2,4-triazol-5-one Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(O)=NN=2)C=2C=C3C(C)=CN(C)C3=CC=2)=C1O MXKIFFBZWXCSSS-UHFFFAOYSA-N 0.000 claims 1
- UBYWHLVHDACFMM-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-(1,3-dimethylindol-5-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(S)=NN=2)C=2C=C3C(C)=CN(C)C3=CC=2)=C1O UBYWHLVHDACFMM-UHFFFAOYSA-N 0.000 claims 1
- LIRCZXORVKKVOJ-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-(1-ethylindol-5-yl)-1H-1,2,4-triazole-5-thione Chemical compound C=1C=C2N(CC)C=CC2=CC=1N1C(S)=NN=C1C1=CC(C(C)C)=C(O)C=C1O LIRCZXORVKKVOJ-UHFFFAOYSA-N 0.000 claims 1
- JANGROUHZNBYRD-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-(1-methylindol-5-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(S)=NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O JANGROUHZNBYRD-UHFFFAOYSA-N 0.000 claims 1
- AWBAVFLOUGHJRJ-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-(1-propan-2-ylindol-4-yl)-1H-1,2,4-triazol-5-one Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(O)=NN=2)C=2C=3C=CN(C=3C=CC=2)C(C)C)=C1O AWBAVFLOUGHJRJ-UHFFFAOYSA-N 0.000 claims 1
- STVGXJKUWLHOGD-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-(1-propylindol-5-yl)-1H-1,2,4-triazole-5-thione Chemical compound C=1C=C2N(CCC)C=CC2=CC=1N1C(S)=NN=C1C1=CC(C(C)C)=C(O)C=C1O STVGXJKUWLHOGD-UHFFFAOYSA-N 0.000 claims 1
- BTGVBRHYZUAKCR-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-(1H-indol-5-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(S)=NN=2)C=2C=C3C=CNC3=CC=2)=C1O BTGVBRHYZUAKCR-UHFFFAOYSA-N 0.000 claims 1
- NDPQZXRORWTRAB-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-(7-methoxy-1-propan-2-ylindol-4-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=2C=CN(C(C)C)C=2C(OC)=CC=C1N1C(S)=NN=C1C1=CC(C(C)C)=C(O)C=C1O NDPQZXRORWTRAB-UHFFFAOYSA-N 0.000 claims 1
- JJGWYOSOCCDKJU-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-[1-methyl-2-(trifluoromethyl)benzimidazol-5-yl]-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(S)=NN=2)C=2C=C3N=C(N(C)C3=CC=2)C(F)(F)F)=C1O JJGWYOSOCCDKJU-UHFFFAOYSA-N 0.000 claims 1
- UIVTZISQSMHJKS-UHFFFAOYSA-N 3-(2,4-dihydroxyphenyl)-4-(1-ethylindol-4-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=CC=C2N(CC)C=CC2=C1N1C(S)=NN=C1C1=CC=C(O)C=C1O UIVTZISQSMHJKS-UHFFFAOYSA-N 0.000 claims 1
- RKFOLXISFIXXRI-UHFFFAOYSA-N 3-(2,4-dihydroxyphenyl)-4-(1-propan-2-ylindol-4-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=CC=C2N(C(C)C)C=CC2=C1N1C(S)=NN=C1C1=CC=C(O)C=C1O RKFOLXISFIXXRI-UHFFFAOYSA-N 0.000 claims 1
- UBBWIIUNTKWYMN-UHFFFAOYSA-N 3-(2,4-dihydroxyphenyl)-4-(1H-indol-4-yl)-1H-1,2,4-triazole-5-thione Chemical compound OC1=CC(O)=CC=C1C1=NN=C(S)N1C1=CC=CC2=C1C=CN2 UBBWIIUNTKWYMN-UHFFFAOYSA-N 0.000 claims 1
- LQKKAHUTPJMJET-UHFFFAOYSA-N 3-(2,4-dihydroxyphenyl)-4-[2-(1-methoxyethyl)-1H-indol-4-yl]-1H-1,2,4-triazole-5-thione Chemical compound C1=CC=C2NC(C(C)OC)=CC2=C1N1C(S)=NN=C1C1=CC=C(O)C=C1O LQKKAHUTPJMJET-UHFFFAOYSA-N 0.000 claims 1
- HVFFXYJWYZFIBV-UHFFFAOYSA-N 3-(5-cyclopropyl-2,4-dihydroxyphenyl)-4-(1,2,3-trimethylindol-5-yl)-1H-1,2,4-triazole-5-thione Chemical compound C=1C=C2N(C)C(C)=C(C)C2=CC=1N1C(S)=NN=C1C(C(=CC=1O)O)=CC=1C1CC1 HVFFXYJWYZFIBV-UHFFFAOYSA-N 0.000 claims 1
- QFROSIGFOALPEM-UHFFFAOYSA-N 3-(5-cyclopropyl-2,4-dihydroxyphenyl)-4-(1,3-dimethylindol-5-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C2C(C)=CN(C)C2=CC=C1N1C(S)=NN=C1C(C(=CC=1O)O)=CC=1C1CC1 QFROSIGFOALPEM-UHFFFAOYSA-N 0.000 claims 1
- CXYAPZNVLMXJNT-UHFFFAOYSA-N 3-(5-cyclopropyl-2,4-dihydroxyphenyl)-4-(1-methylindol-5-yl)-1H-1,2,4-triazole-5-thione Chemical compound C=1C=C2N(C)C=CC2=CC=1N1C(S)=NN=C1C(C(=CC=1O)O)=CC=1C1CC1 CXYAPZNVLMXJNT-UHFFFAOYSA-N 0.000 claims 1
- REUUXTDHNKRGOI-UHFFFAOYSA-N 3-(5-cyclopropyl-2,4-dihydroxyphenyl)-4-(7-methoxy-1-propan-2-ylindol-4-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=2C=CN(C(C)C)C=2C(OC)=CC=C1N1C(S)=NN=C1C(C(=CC=1O)O)=CC=1C1CC1 REUUXTDHNKRGOI-UHFFFAOYSA-N 0.000 claims 1
- UATPOJPGMXSVGQ-UHFFFAOYSA-N 3-(5-cyclopropyl-2,4-dihydroxyphenyl)-4-(7-methoxy-1-propylindol-4-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=CC(OC)=C2N(CCC)C=CC2=C1N1C(S)=NN=C1C(C(=CC=1O)O)=CC=1C1CC1 UATPOJPGMXSVGQ-UHFFFAOYSA-N 0.000 claims 1
- VDODPAGJCVTEJQ-UHFFFAOYSA-N 3-(5-cyclopropyl-2,4-dihydroxyphenyl)-4-[1-(1-methylcyclopropyl)indol-4-yl]-1H-1,2,4-triazole-5-thione Chemical compound C1=CC2=C(N3C(=NN=C3S)C=3C(=CC(O)=C(C4CC4)C=3)O)C=CC=C2N1C1(C)CC1 VDODPAGJCVTEJQ-UHFFFAOYSA-N 0.000 claims 1
- STLUOXMEJVFZCP-UHFFFAOYSA-N 3-(5-ethyl-2,4-dihydroxyphenyl)-4-(1,2,3-trimethylindol-5-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(CC)=CC(C=2N(C(S)=NN=2)C=2C=C3C(C)=C(C)N(C)C3=CC=2)=C1O STLUOXMEJVFZCP-UHFFFAOYSA-N 0.000 claims 1
- FODKQXTYMMCSPC-UHFFFAOYSA-N 3-(5-ethyl-2,4-dihydroxyphenyl)-4-(1-ethyl-2-methylbenzimidazol-5-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(CC)=CC(C=2N(C(S)=NN=2)C=2C=C3N=C(C)N(CC)C3=CC=2)=C1O FODKQXTYMMCSPC-UHFFFAOYSA-N 0.000 claims 1
- YUZVSLHCEHKSQJ-UHFFFAOYSA-N 3-(5-ethyl-2,4-dihydroxyphenyl)-4-(1-hexylindol-4-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=CC=C2N(CCCCCC)C=CC2=C1N1C(S)=NN=C1C1=CC(CC)=C(O)C=C1O YUZVSLHCEHKSQJ-UHFFFAOYSA-N 0.000 claims 1
- UOZMPLARHDBOPI-UHFFFAOYSA-N 3-(5-ethyl-2,4-dihydroxyphenyl)-4-(1-methyl-3-propan-2-ylindol-5-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(CC)=CC(C=2N(C(S)=NN=2)C=2C=C3C(C(C)C)=CN(C)C3=CC=2)=C1O UOZMPLARHDBOPI-UHFFFAOYSA-N 0.000 claims 1
- INSPZFPAIAETMI-UHFFFAOYSA-N 3-(5-ethyl-2,4-dihydroxyphenyl)-4-(1-methylindol-5-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(CC)=CC(C=2N(C(S)=NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O INSPZFPAIAETMI-UHFFFAOYSA-N 0.000 claims 1
- OLLRLHGHUWXAFP-UHFFFAOYSA-N 3-(5-ethyl-2,4-dihydroxyphenyl)-4-(1-pentylindol-4-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=CC=C2N(CCCCC)C=CC2=C1N1C(S)=NN=C1C1=CC(CC)=C(O)C=C1O OLLRLHGHUWXAFP-UHFFFAOYSA-N 0.000 claims 1
- QZCQHJMGZJLICK-UHFFFAOYSA-N 3-(5-ethyl-2,4-dihydroxyphenyl)-4-(1-propan-2-ylindol-4-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(CC)=CC(C=2N(C(S)=NN=2)C=2C=3C=CN(C=3C=CC=2)C(C)C)=C1O QZCQHJMGZJLICK-UHFFFAOYSA-N 0.000 claims 1
- LBVJBJFVUWQRLE-UHFFFAOYSA-N 3-(5-ethyl-2,4-dihydroxyphenyl)-4-(1-propylindol-4-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=CC=C2N(CCC)C=CC2=C1N1C(S)=NN=C1C1=CC(CC)=C(O)C=C1O LBVJBJFVUWQRLE-UHFFFAOYSA-N 0.000 claims 1
- QSFLGQYOSRZJAQ-UHFFFAOYSA-N 3-(5-ethyl-2,4-dihydroxyphenyl)-4-(3-ethyl-1-methylindol-5-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C2C(CC)=CN(C)C2=CC=C1N1C(S)=NN=C1C1=CC(CC)=C(O)C=C1O QSFLGQYOSRZJAQ-UHFFFAOYSA-N 0.000 claims 1
- NZZXFHSCKWJAQF-UHFFFAOYSA-N 3-(5-ethyl-2,4-dihydroxyphenyl)-4-(3-ethyl-2-methylbenzimidazol-5-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(CC)=CC(C=2N(C(S)=NN=2)C=2C=C3N(CC)C(C)=NC3=CC=2)=C1O NZZXFHSCKWJAQF-UHFFFAOYSA-N 0.000 claims 1
- ZBXXGZDCLQEVEQ-UHFFFAOYSA-N 3-(5-ethyl-2,4-dihydroxyphenyl)-4-(7-methoxy-1-propan-2-ylindol-4-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(CC)=CC(C=2N(C(S)=NN=2)C=2C=3C=CN(C=3C(OC)=CC=2)C(C)C)=C1O ZBXXGZDCLQEVEQ-UHFFFAOYSA-N 0.000 claims 1
- QYVIZOQFOBGAHW-UHFFFAOYSA-N 3-(5-ethyl-2,4-dihydroxyphenyl)-4-(7-methoxy-2-methyl-1-benzofuran-4-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(CC)=CC(C=2N(C(S)=NN=2)C=2C=3C=C(C)OC=3C(OC)=CC=2)=C1O QYVIZOQFOBGAHW-UHFFFAOYSA-N 0.000 claims 1
- JJEYWCWGANAGDC-UHFFFAOYSA-N 3-(5-tert-butyl-2,4-dihydroxyphenyl)-4-(7-methoxy-1-propan-2-ylindol-4-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=2C=CN(C(C)C)C=2C(OC)=CC=C1N1C(S)=NN=C1C1=CC(C(C)(C)C)=C(O)C=C1O JJEYWCWGANAGDC-UHFFFAOYSA-N 0.000 claims 1
- ARFPAOWQRMCLCC-UHFFFAOYSA-N 4-(1,3-dimethylindol-5-yl)-3-(5-ethyl-2,4-dihydroxyphenyl)-1H-1,2,4-triazol-5-one Chemical compound C1=C(O)C(CC)=CC(C=2N(C(O)=NN=2)C=2C=C3C(C)=CN(C)C3=CC=2)=C1O ARFPAOWQRMCLCC-UHFFFAOYSA-N 0.000 claims 1
- PCYXGRPZGRZCMY-UHFFFAOYSA-N 4-(1,3-dimethylindol-5-yl)-3-(5-ethyl-2,4-dihydroxyphenyl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(CC)=CC(C=2N(C(S)=NN=2)C=2C=C3C(C)=CN(C)C3=CC=2)=C1O PCYXGRPZGRZCMY-UHFFFAOYSA-N 0.000 claims 1
- CXWAUYMEDCGIRL-UHFFFAOYSA-N 4-(1-benzofuran-5-yl)-3-(5-ethyl-2,4-dihydroxyphenyl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(CC)=CC(C=2N(C(S)=NN=2)C=2C=C3C=COC3=CC=2)=C1O CXWAUYMEDCGIRL-UHFFFAOYSA-N 0.000 claims 1
- GXDNJALLRJLOSU-UHFFFAOYSA-N 4-(1-butylindol-4-yl)-3-(5-ethyl-2,4-dihydroxyphenyl)-1H-1,2,4-triazole-5-thione Chemical compound C1=CC=C2N(CCCC)C=CC2=C1N1C(S)=NN=C1C1=CC(CC)=C(O)C=C1O GXDNJALLRJLOSU-UHFFFAOYSA-N 0.000 claims 1
- PZBMTCSNWKKAJE-UHFFFAOYSA-N 4-(2,3-dimethyl-1-propylindol-5-yl)-3-(5-ethyl-2,4-dihydroxyphenyl)-1H-1,2,4-triazole-5-thione Chemical compound C=1C=C2N(CCC)C(C)=C(C)C2=CC=1N1C(S)=NN=C1C1=CC(CC)=C(O)C=C1O PZBMTCSNWKKAJE-UHFFFAOYSA-N 0.000 claims 1
- DVYPKVKKDQJXJG-UHFFFAOYSA-N 4-(2,3-dimethyl-1H-indol-5-yl)-3-(5-ethyl-2,4-dihydroxyphenyl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(CC)=CC(C=2N(C(S)=NN=2)C=2C=C3C(C)=C(C)NC3=CC=2)=C1O DVYPKVKKDQJXJG-UHFFFAOYSA-N 0.000 claims 1
- KXFUDIWUTBTKLV-UHFFFAOYSA-N 4-(2-methylpropyl)-6-(5-naphthalen-1-yl-4-sulfanyltriazol-1-yl)benzene-1,3-diol Chemical compound C1=C(O)C(CC(C)C)=CC(N2C(=C(S)N=N2)C=2C3=CC=CC=C3C=CC=2)=C1O KXFUDIWUTBTKLV-UHFFFAOYSA-N 0.000 claims 1
- QCIHXLGRPQWNSX-UHFFFAOYSA-N 4-(4-amino-5-naphthalen-1-yltriazol-1-yl)-6-ethylbenzene-1,3-diol Chemical compound C1=C(O)C(CC)=CC(N2C(=C(N)N=N2)C=2C3=CC=CC=C3C=CC=2)=C1O QCIHXLGRPQWNSX-UHFFFAOYSA-N 0.000 claims 1
- OPJYRBDVYGLNHO-UHFFFAOYSA-N 4-(4-hydroxy-5-naphthalen-1-yltriazol-1-yl)benzene-1,3-diol Chemical compound C=1C=CC2=CC=CC=C2C=1C1=C(O)N=NN1C1=CC=C(O)C=C1O OPJYRBDVYGLNHO-UHFFFAOYSA-N 0.000 claims 1
- UCSABVSCHAFQBD-UHFFFAOYSA-N 4-(5-anthracen-1-yl-4-sulfanyltriazol-1-yl)benzene-1,3-diol Chemical compound OC1=CC(O)=CC=C1N1C(C=2C3=CC4=CC=CC=C4C=C3C=CC=2)=C(S)N=N1 UCSABVSCHAFQBD-UHFFFAOYSA-N 0.000 claims 1
- BLNMRNWLCPEDOW-UHFFFAOYSA-N 4-(5-cyclopentyl-4-hydroxytriazol-1-yl)benzene-1,3-diol Chemical compound OC=1N=NN(C=2C(=CC(O)=CC=2)O)C=1C1CCCC1 BLNMRNWLCPEDOW-UHFFFAOYSA-N 0.000 claims 1
- YVRPYGICLXJRFN-UHFFFAOYSA-N 4-(5-isoquinolin-5-yl-4-sulfanyltriazol-1-yl)benzene-1,3-diol Chemical compound OC1=CC(O)=CC=C1N1C(C=2C3=CC=NC=C3C=CC=2)=C(S)N=N1 YVRPYGICLXJRFN-UHFFFAOYSA-N 0.000 claims 1
- CUKPXKZOHRXOEQ-UHFFFAOYSA-N 4-(5-naphthalen-1-yl-4-sulfanyltriazol-1-yl)-2-propylbenzene-1,3-diol Chemical compound CCCC1=C(O)C=CC(N2C(=C(S)N=N2)C=2C3=CC=CC=C3C=CC=2)=C1O CUKPXKZOHRXOEQ-UHFFFAOYSA-N 0.000 claims 1
- KGASZJKMPPWQDZ-UHFFFAOYSA-N 4-(5-naphthalen-1-yl-4-sulfanyltriazol-1-yl)-6-propylbenzene-1,3-diol Chemical compound C1=C(O)C(CCC)=CC(N2C(=C(S)N=N2)C=2C3=CC=CC=C3C=CC=2)=C1O KGASZJKMPPWQDZ-UHFFFAOYSA-N 0.000 claims 1
- RLBDQDJNWAUKLO-UHFFFAOYSA-N 4-(5-naphthalen-1-yl-4-sulfanyltriazol-1-yl)pyridin-3-ol Chemical compound OC1=CN=CC=C1N1C(C=2C3=CC=CC=C3C=CC=2)=C(S)N=N1 RLBDQDJNWAUKLO-UHFFFAOYSA-N 0.000 claims 1
- XATLRWMNEGHRPS-UHFFFAOYSA-N 4-(5-naphthalen-2-yl-4-sulfanyltriazol-1-yl)benzene-1,3-diol Chemical compound OC1=CC(O)=CC=C1N1C(C=2C=C3C=CC=CC3=CC=2)=C(S)N=N1 XATLRWMNEGHRPS-UHFFFAOYSA-N 0.000 claims 1
- DLBQZAZKTSKVFJ-UHFFFAOYSA-N 4-(5-pyren-1-yl-4-sulfanyltriazol-1-yl)benzene-1,3-diol Chemical compound OC1=CC(O)=CC=C1N1C(C=2C3=CC=C4C=CC=C5C=CC(C3=C54)=CC=2)=C(S)N=N1 DLBQZAZKTSKVFJ-UHFFFAOYSA-N 0.000 claims 1
- MSHWXIGOOVPDPM-UHFFFAOYSA-N 4-(5-quinolin-5-yl-4-sulfanyltriazol-1-yl)benzene-1,3-diol Chemical compound OC1=CC(O)=CC=C1N1C(C=2C3=CC=CN=C3C=CC=2)=C(S)N=N1 MSHWXIGOOVPDPM-UHFFFAOYSA-N 0.000 claims 1
- IEXWEVLAAWUJAO-UHFFFAOYSA-N 4-(7-ethoxy-1-propan-2-ylindol-4-yl)-3-(5-ethyl-2,4-dihydroxyphenyl)-1H-1,2,4-triazole-5-thione Chemical compound C1=2C=CN(C(C)C)C=2C(OCC)=CC=C1N1C(S)=NN=C1C1=CC(CC)=C(O)C=C1O IEXWEVLAAWUJAO-UHFFFAOYSA-N 0.000 claims 1
- NKMBQLZOMVTUEJ-UHFFFAOYSA-N 4-[3-(2,4-dihydroxy-5-methoxyphenyl)-5-(sulfamoylamino)triazol-4-yl]-1-propan-2-ylbenzimidazole Chemical compound C1=C(O)C(OC)=CC(N2C(=C(NS(N)(=O)=O)N=N2)C=2C=3N=CN(C=3C=CC=2)C(C)C)=C1O NKMBQLZOMVTUEJ-UHFFFAOYSA-N 0.000 claims 1
- JNQALWWIUZZILK-UHFFFAOYSA-N 4-[3-(2,4-dihydroxyphenyl)-5-sulfanylidene-1H-1,2,4-triazol-4-yl]-N,N-dimethylindole-1-carboxamide Chemical compound C1=CC=C2N(C(=O)N(C)C)C=CC2=C1N1C(S)=NN=C1C1=CC=C(O)C=C1O JNQALWWIUZZILK-UHFFFAOYSA-N 0.000 claims 1
- IABAOISHPHFQON-UHFFFAOYSA-N 4-[3-(2,4-dihydroxyphenyl)-5-sulfanyltriazol-4-yl]-n,n-dimethylindole-1-carboxamide Chemical compound C1=CC=C2N(C(=O)N(C)C)C=CC2=C1C1=C(S)N=NN1C1=CC=C(O)C=C1O IABAOISHPHFQON-UHFFFAOYSA-N 0.000 claims 1
- QDDVQWCSTMJEKR-UHFFFAOYSA-N 4-[3-(2,4-dihydroxyphenyl)-5-sulfanyltriazol-4-yl]-n,n-dimethylnaphthalene-1-carboxamide Chemical compound C12=CC=CC=C2C(C(=O)N(C)C)=CC=C1C1=C(S)N=NN1C1=CC=C(O)C=C1O QDDVQWCSTMJEKR-UHFFFAOYSA-N 0.000 claims 1
- ACZLMOIXHSSPKD-UHFFFAOYSA-N 4-[3-(2,4-dihydroxyphenyl)-5-sulfanyltriazol-4-yl]naphthalene-1-carboxylic acid Chemical compound C12=CC=CC=C2C(C(=O)O)=CC=C1C1=C(S)N=NN1C1=CC=C(O)C=C1O ACZLMOIXHSSPKD-UHFFFAOYSA-N 0.000 claims 1
- DKILYVCIXQHTIU-UHFFFAOYSA-N 4-[3-(5-ethyl-2,4-dihydroxyphenyl)-5-sulfanyltriazol-4-yl]-n,n-dimethylindole-1-carboxamide Chemical compound C1=C(O)C(CC)=CC(N2C(=C(S)N=N2)C=2C=3C=CN(C=3C=CC=2)C(=O)N(C)C)=C1O DKILYVCIXQHTIU-UHFFFAOYSA-N 0.000 claims 1
- ZGEIHFVCPLKJGN-UHFFFAOYSA-N 4-[4-amino-5-(1-propan-2-ylindol-4-yl)triazol-1-yl]-6-ethylbenzene-1,3-diol Chemical compound C1=C(O)C(CC)=CC(N2C(=C(N)N=N2)C=2C=3C=CN(C=3C=CC=2)C(C)C)=C1O ZGEIHFVCPLKJGN-UHFFFAOYSA-N 0.000 claims 1
- FQVFPDYOLRZLCU-UHFFFAOYSA-N 4-[4-amino-5-(3-methoxyphenyl)triazol-1-yl]-6-ethylbenzene-1,3-diol Chemical compound C1=C(O)C(CC)=CC(N2C(=C(N)N=N2)C=2C=C(OC)C=CC=2)=C1O FQVFPDYOLRZLCU-UHFFFAOYSA-N 0.000 claims 1
- WBWYSAZLYDMMLR-UHFFFAOYSA-N 4-[4-hydroxy-5-(7H-purin-6-yl)triazol-1-yl]benzene-1,3-diol Chemical compound N=1C=NC=2NC=NC=2C=1C1=C(O)N=NN1C1=CC=C(O)C=C1O WBWYSAZLYDMMLR-UHFFFAOYSA-N 0.000 claims 1
- SADCOTRUSFBBIW-UHFFFAOYSA-N 4-[4-hydroxy-5-[2-(2H-tetrazol-5-yl)phenyl]triazol-1-yl]benzene-1,3-diol Chemical compound OC=1N=NN(C=2C(=CC(O)=CC=2)O)C=1C1=CC=CC=C1C1=NN=NN1 SADCOTRUSFBBIW-UHFFFAOYSA-N 0.000 claims 1
- QNYAXJFEOBJPBA-UHFFFAOYSA-N 4-[4-sulfanyl-5-(1,2,3,4-tetrahydronaphthalen-1-yl)triazol-1-yl]benzene-1,3-diol Chemical compound OC1=CC(O)=CC=C1N1C(C2C3=CC=CC=C3CCC2)=C(S)N=N1 QNYAXJFEOBJPBA-UHFFFAOYSA-N 0.000 claims 1
- LLHQBJNAVFDQQI-UHFFFAOYSA-N 4-[4-sulfanyl-5-(5,6,7,8-tetrahydronaphthalen-1-yl)triazol-1-yl]benzene-1,3-diol Chemical compound OC1=CC(O)=CC=C1N1C(C=2C=3CCCCC=3C=CC=2)=C(S)N=N1 LLHQBJNAVFDQQI-UHFFFAOYSA-N 0.000 claims 1
- ZFEACFROXXATCR-UHFFFAOYSA-N 4-[5-(1,3-benzothiazol-4-yl)-4-hydroxytriazol-1-yl]benzene-1,3-diol Chemical compound C=1C=CC=2SC=NC=2C=1C1=C(O)N=NN1C1=CC=C(O)C=C1O ZFEACFROXXATCR-UHFFFAOYSA-N 0.000 claims 1
- SNVNFLOSWVTBNK-UHFFFAOYSA-N 4-[5-(1-ethylindol-4-yl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound C1=CC=C2N(CC)C=CC2=C1C1=C(S)N=NN1C1=CC=C(O)C=C1O SNVNFLOSWVTBNK-UHFFFAOYSA-N 0.000 claims 1
- GMWJTMWXXZVOJW-UHFFFAOYSA-N 4-[5-(1-propan-2-ylindol-4-yl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound C1=CC=C2N(C(C)C)C=CC2=C1C1=C(S)N=NN1C1=CC=C(O)C=C1O GMWJTMWXXZVOJW-UHFFFAOYSA-N 0.000 claims 1
- IDUFMJNUWVFMFH-UHFFFAOYSA-N 4-[5-(1H-indol-4-yl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound OC1=CC(O)=CC=C1N1C(C=2C=3C=CNC=3C=CC=2)=C(S)N=N1 IDUFMJNUWVFMFH-UHFFFAOYSA-N 0.000 claims 1
- GFWWEKGQQZLSOM-UHFFFAOYSA-N 4-[5-(2,3-dichlorophenyl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound OC1=CC(O)=CC=C1N1C(C=2C(=C(Cl)C=CC=2)Cl)=C(S)N=N1 GFWWEKGQQZLSOM-UHFFFAOYSA-N 0.000 claims 1
- BLJKSFXMWXEHAW-UHFFFAOYSA-N 4-[5-(2,3-difluorophenyl)-4-hydroxytriazol-1-yl]benzene-1,3-diol Chemical compound OC=1N=NN(C=2C(=CC(O)=CC=2)O)C=1C1=CC=CC(F)=C1F BLJKSFXMWXEHAW-UHFFFAOYSA-N 0.000 claims 1
- FGGAIZKNXOHTHQ-UHFFFAOYSA-N 4-[5-(2,3-dimethoxyphenyl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound COC1=CC=CC(C=2N(N=NC=2S)C=2C(=CC(O)=CC=2)O)=C1OC FGGAIZKNXOHTHQ-UHFFFAOYSA-N 0.000 claims 1
- NLHLYUFHTZQGLQ-UHFFFAOYSA-N 4-[5-(2,3-dimethyl-1H-indol-4-yl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound C=12C(C)=C(C)NC2=CC=CC=1C1=C(S)N=NN1C1=CC=C(O)C=C1O NLHLYUFHTZQGLQ-UHFFFAOYSA-N 0.000 claims 1
- FIGUGPFIHOZTMB-UHFFFAOYSA-N 4-[5-(2,3-dimethyl-1H-indol-5-yl)-4-sulfanyltriazol-1-yl]-6-ethylbenzene-1,3-diol Chemical compound C1=C(O)C(CC)=CC(N2C(=C(S)N=N2)C=2C=C3C(C)=C(C)NC3=CC=2)=C1O FIGUGPFIHOZTMB-UHFFFAOYSA-N 0.000 claims 1
- LAYGIGZQEPOADS-UHFFFAOYSA-N 4-[5-(2,3-dimethylphenyl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound CC1=CC=CC(C=2N(N=NC=2S)C=2C(=CC(O)=CC=2)O)=C1C LAYGIGZQEPOADS-UHFFFAOYSA-N 0.000 claims 1
- SKUHKFMIHMMXBR-UHFFFAOYSA-N 4-[5-(2,4-dimethylphenyl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound CC1=CC(C)=CC=C1C1=C(S)N=NN1C1=CC=C(O)C=C1O SKUHKFMIHMMXBR-UHFFFAOYSA-N 0.000 claims 1
- JTODPTADEPPHBY-UHFFFAOYSA-N 4-[5-(2,6-diethylphenyl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound CCC1=CC=CC(CC)=C1C1=C(S)N=NN1C1=CC=C(O)C=C1O JTODPTADEPPHBY-UHFFFAOYSA-N 0.000 claims 1
- UDWQTWCDZDMCQV-UHFFFAOYSA-N 4-[5-(2-chlorophenyl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound OC1=CC(O)=CC=C1N1C(C=2C(=CC=CC=2)Cl)=C(S)N=N1 UDWQTWCDZDMCQV-UHFFFAOYSA-N 0.000 claims 1
- PFGBGZNNIUXLHX-UHFFFAOYSA-N 4-[5-(2-ethyl-6-methylphenyl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound CCC1=CC=CC(C)=C1C1=C(S)N=NN1C1=CC=C(O)C=C1O PFGBGZNNIUXLHX-UHFFFAOYSA-N 0.000 claims 1
- QXUTWAVVVCEISA-UHFFFAOYSA-N 4-[5-(2-ethylphenyl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound CCC1=CC=CC=C1C1=C(S)N=NN1C1=CC=C(O)C=C1O QXUTWAVVVCEISA-UHFFFAOYSA-N 0.000 claims 1
- XFBASRVLYNFUAJ-UHFFFAOYSA-N 4-[5-(2-methoxyphenyl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound COC1=CC=CC=C1C1=C(S)N=NN1C1=CC=C(O)C=C1O XFBASRVLYNFUAJ-UHFFFAOYSA-N 0.000 claims 1
- GVBQCYLOKWOIKO-UHFFFAOYSA-N 4-[5-(2-methylquinolin-4-yl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound C=12C=CC=CC2=NC(C)=CC=1C1=C(S)N=NN1C1=CC=C(O)C=C1O GVBQCYLOKWOIKO-UHFFFAOYSA-N 0.000 claims 1
- BEXDOQZVKJBYCF-UHFFFAOYSA-N 4-[5-(2-methylsulfanylphenyl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound CSC1=CC=CC=C1C1=C(S)N=NN1C1=CC=C(O)C=C1O BEXDOQZVKJBYCF-UHFFFAOYSA-N 0.000 claims 1
- WVGFMPBFGBVGGH-UHFFFAOYSA-N 4-[5-(2-phenylphenyl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound OC1=CC(O)=CC=C1N1C(C=2C(=CC=CC=2)C=2C=CC=CC=2)=C(S)N=N1 WVGFMPBFGBVGGH-UHFFFAOYSA-N 0.000 claims 1
- RMMQOLPSKHIUBO-UHFFFAOYSA-N 4-[5-(3,5-dimethoxyphenyl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound COC1=CC(OC)=CC(C=2N(N=NC=2S)C=2C(=CC(O)=CC=2)O)=C1 RMMQOLPSKHIUBO-UHFFFAOYSA-N 0.000 claims 1
- XQKTWAQABRVKTF-UHFFFAOYSA-N 4-[5-(3,5-ditert-butylphenyl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound CC(C)(C)C1=CC(C(C)(C)C)=CC(C=2N(N=NC=2S)C=2C(=CC(O)=CC=2)O)=C1 XQKTWAQABRVKTF-UHFFFAOYSA-N 0.000 claims 1
- FBBWMYKMWMRPFK-UHFFFAOYSA-N 4-[5-(3-chloro-2-methoxyphenyl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound COC1=C(Cl)C=CC=C1C1=C(S)N=NN1C1=CC=C(O)C=C1O FBBWMYKMWMRPFK-UHFFFAOYSA-N 0.000 claims 1
- MGAZRBVNNFEALV-UHFFFAOYSA-N 4-[5-(3-chlorophenyl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound OC1=CC(O)=CC=C1N1C(C=2C=C(Cl)C=CC=2)=C(S)N=N1 MGAZRBVNNFEALV-UHFFFAOYSA-N 0.000 claims 1
- IEQNGPBBEOUZJB-UHFFFAOYSA-N 4-[5-(3-fluorophenyl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound OC1=CC(O)=CC=C1N1C(C=2C=C(F)C=CC=2)=C(S)N=N1 IEQNGPBBEOUZJB-UHFFFAOYSA-N 0.000 claims 1
- IOMQEKVQBSWHCU-UHFFFAOYSA-N 4-[5-(3-methoxyphenyl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound COC1=CC=CC(C=2N(N=NC=2S)C=2C(=CC(O)=CC=2)O)=C1 IOMQEKVQBSWHCU-UHFFFAOYSA-N 0.000 claims 1
- KGYRPCNKAODAAO-UHFFFAOYSA-N 4-[5-(3-methylphenyl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound CC1=CC=CC(C=2N(N=NC=2S)C=2C(=CC(O)=CC=2)O)=C1 KGYRPCNKAODAAO-UHFFFAOYSA-N 0.000 claims 1
- DNIKXDFMZZPLLP-UHFFFAOYSA-N 4-[5-(3-phenylphenyl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound OC1=CC(O)=CC=C1N1C(C=2C=C(C=CC=2)C=2C=CC=CC=2)=C(S)N=N1 DNIKXDFMZZPLLP-UHFFFAOYSA-N 0.000 claims 1
- XWGFZOWEULZHON-UHFFFAOYSA-N 4-[5-(3-tert-butyl-4-methoxyphenyl)-4-sulfanyltriazol-1-yl]-6-ethylbenzene-1,3-diol Chemical compound C1=C(O)C(CC)=CC(N2C(=C(S)N=N2)C=2C=C(C(OC)=CC=2)C(C)(C)C)=C1O XWGFZOWEULZHON-UHFFFAOYSA-N 0.000 claims 1
- CFEVGPLCJGLNTR-UHFFFAOYSA-N 4-[5-(4-bromo-2-methylphenyl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound CC1=CC(Br)=CC=C1C1=C(S)N=NN1C1=CC=C(O)C=C1O CFEVGPLCJGLNTR-UHFFFAOYSA-N 0.000 claims 1
- WBIAOWDZWHOQLR-UHFFFAOYSA-N 4-[5-(4-butyl-2-methylphenyl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound CC1=CC(CCCC)=CC=C1C1=C(S)N=NN1C1=CC=C(O)C=C1O WBIAOWDZWHOQLR-UHFFFAOYSA-N 0.000 claims 1
- BORCHZNOBITQAC-UHFFFAOYSA-N 4-[5-(4-chloronaphthalen-1-yl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound OC1=CC(O)=CC=C1N1C(C=2C3=CC=CC=C3C(Cl)=CC=2)=C(S)N=N1 BORCHZNOBITQAC-UHFFFAOYSA-N 0.000 claims 1
- DYUCEMVHADUUHX-UHFFFAOYSA-N 4-[5-(4-chlorophenyl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound OC1=CC(O)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=C(S)N=N1 DYUCEMVHADUUHX-UHFFFAOYSA-N 0.000 claims 1
- UATJXGDPDCSCQW-UHFFFAOYSA-N 4-[5-(4-fluoro-2-methylphenyl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound CC1=CC(F)=CC=C1C1=C(S)N=NN1C1=CC=C(O)C=C1O UATJXGDPDCSCQW-UHFFFAOYSA-N 0.000 claims 1
- MYBVWYRIMYLOCV-UHFFFAOYSA-N 4-[5-(4-fluorophenyl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound OC1=CC(O)=CC=C1N1C(C=2C=CC(F)=CC=2)=C(S)N=N1 MYBVWYRIMYLOCV-UHFFFAOYSA-N 0.000 claims 1
- GYKMQTVNNOLUHW-UHFFFAOYSA-N 4-[5-(4-hydroxynaphthalen-1-yl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound OC1=CC(O)=CC=C1N1C(C=2C3=CC=CC=C3C(O)=CC=2)=C(S)N=N1 GYKMQTVNNOLUHW-UHFFFAOYSA-N 0.000 claims 1
- MJULUTAPKWSYCL-UHFFFAOYSA-N 4-[5-(4-methylphenyl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound C1=CC(C)=CC=C1C1=C(S)N=NN1C1=CC=C(O)C=C1O MJULUTAPKWSYCL-UHFFFAOYSA-N 0.000 claims 1
- HXMGXJOPXYTAPQ-UHFFFAOYSA-N 4-[5-(4-octoxyphenyl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound C1=CC(OCCCCCCCC)=CC=C1C1=C(S)N=NN1C1=CC=C(O)C=C1O HXMGXJOPXYTAPQ-UHFFFAOYSA-N 0.000 claims 1
- MSKPLRAWJKDVMF-UHFFFAOYSA-N 4-[5-(4-pentoxyphenyl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound C1=CC(OCCCCC)=CC=C1C1=C(S)N=NN1C1=CC=C(O)C=C1O MSKPLRAWJKDVMF-UHFFFAOYSA-N 0.000 claims 1
- HCKOIBRUVHWONE-UHFFFAOYSA-N 4-[5-(4-propan-2-yloxynaphthalen-1-yl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound C12=CC=CC=C2C(OC(C)C)=CC=C1C1=C(S)N=NN1C1=CC=C(O)C=C1O HCKOIBRUVHWONE-UHFFFAOYSA-N 0.000 claims 1
- PQMIPBAOVWAVPP-UHFFFAOYSA-N 4-[5-(4-propoxynaphthalen-1-yl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound C12=CC=CC=C2C(OCCC)=CC=C1C1=C(S)N=NN1C1=CC=C(O)C=C1O PQMIPBAOVWAVPP-UHFFFAOYSA-N 0.000 claims 1
- WSHPTVJCZQTQFG-UHFFFAOYSA-N 4-[5-(5-propan-2-yloxynaphthalen-1-yl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound C1=CC=C2C(OC(C)C)=CC=CC2=C1C1=C(S)N=NN1C1=CC=C(O)C=C1O WSHPTVJCZQTQFG-UHFFFAOYSA-N 0.000 claims 1
- KKQMXQYSXVEDGZ-UHFFFAOYSA-N 4-[5-(5-propoxynaphthalen-1-yl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound C1=CC=C2C(OCCC)=CC=CC2=C1C1=C(S)N=NN1C1=CC=C(O)C=C1O KKQMXQYSXVEDGZ-UHFFFAOYSA-N 0.000 claims 1
- AGIGIYOJBUVMCA-UHFFFAOYSA-N 4-[5-(6-ethoxynaphthalen-1-yl)-4-sulfanyltriazol-1-yl]benzene-1,2-diol Chemical compound C=1C=CC2=CC(OCC)=CC=C2C=1C1=C(S)N=NN1C1=CC=C(O)C(O)=C1 AGIGIYOJBUVMCA-UHFFFAOYSA-N 0.000 claims 1
- NMRQPWDQZAQXAX-UHFFFAOYSA-N 4-[5-(6-methoxynaphthalen-1-yl)-4-sulfanyltriazol-1-yl]benzene-1,2-diol Chemical compound C=1C=CC2=CC(OC)=CC=C2C=1C1=C(S)N=NN1C1=CC=C(O)C(O)=C1 NMRQPWDQZAQXAX-UHFFFAOYSA-N 0.000 claims 1
- WKJJKBIVZAEMLW-UHFFFAOYSA-N 4-[5-(6-propan-2-yloxynaphthalen-1-yl)-4-sulfanyltriazol-1-yl]benzene-1,2-diol Chemical compound C=1C=CC2=CC(OC(C)C)=CC=C2C=1C1=C(S)N=NN1C1=CC=C(O)C(O)=C1 WKJJKBIVZAEMLW-UHFFFAOYSA-N 0.000 claims 1
- ONQHVMVORXLSLJ-UHFFFAOYSA-N 4-[5-(6-propoxynaphthalen-1-yl)-4-sulfanyltriazol-1-yl]benzene-1,2-diol Chemical compound C=1C=CC2=CC(OCCC)=CC=C2C=1C1=C(S)N=NN1C1=CC=C(O)C(O)=C1 ONQHVMVORXLSLJ-UHFFFAOYSA-N 0.000 claims 1
- LHDPWURQUIYLBA-UHFFFAOYSA-N 4-[5-(7-ethoxynaphthalen-1-yl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound C12=CC(OCC)=CC=C2C=CC=C1C1=C(S)N=NN1C1=CC=C(O)C=C1O LHDPWURQUIYLBA-UHFFFAOYSA-N 0.000 claims 1
- XGQZFVLUAZHCHS-UHFFFAOYSA-N 4-[5-(7-methoxynaphthalen-1-yl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound C12=CC(OC)=CC=C2C=CC=C1C1=C(S)N=NN1C1=CC=C(O)C=C1O XGQZFVLUAZHCHS-UHFFFAOYSA-N 0.000 claims 1
- AUYJAMQXNYJNLX-UHFFFAOYSA-N 4-[5-(7-propan-2-yloxynaphthalen-1-yl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound C12=CC(OC(C)C)=CC=C2C=CC=C1C1=C(S)N=NN1C1=CC=C(O)C=C1O AUYJAMQXNYJNLX-UHFFFAOYSA-N 0.000 claims 1
- NVRGGYIKLGTMAI-UHFFFAOYSA-N 4-[5-(7-propoxynaphthalen-1-yl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound C12=CC(OCCC)=CC=C2C=CC=C1C1=C(S)N=NN1C1=CC=C(O)C=C1O NVRGGYIKLGTMAI-UHFFFAOYSA-N 0.000 claims 1
- MQDJHKNSGMPXII-UHFFFAOYSA-N 4-[5-(naphthalen-1-ylmethyl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound OC1=CC(O)=CC=C1N1C(CC=2C3=CC=CC=C3C=CC=2)=C(S)N=N1 MQDJHKNSGMPXII-UHFFFAOYSA-N 0.000 claims 1
- KGBBGIKBWYHOML-UHFFFAOYSA-N 4-[5-[1-(2-methoxyethoxy)indol-4-yl]-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound C1=CC=C2N(OCCOC)C=CC2=C1C1=C(S)N=NN1C1=CC=C(O)C=C1O KGBBGIKBWYHOML-UHFFFAOYSA-N 0.000 claims 1
- PWPJYZRIWWTTQQ-UHFFFAOYSA-N 4-[5-[2,6-di(propan-2-yl)phenyl]-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1C1=C(S)N=NN1C1=CC=C(O)C=C1O PWPJYZRIWWTTQQ-UHFFFAOYSA-N 0.000 claims 1
- XRCMYUBITUDKBQ-UHFFFAOYSA-N 4-[5-[4-(2-methoxyethoxy)naphthalen-1-yl]-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound C12=CC=CC=C2C(OCCOC)=CC=C1C1=C(S)N=NN1C1=CC=C(O)C=C1O XRCMYUBITUDKBQ-UHFFFAOYSA-N 0.000 claims 1
- ZSZIANUMRDXGDW-UHFFFAOYSA-N 4-[5-[5-(hydroxymethyl)-2-methylphenyl]-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound CC1=CC=C(CO)C=C1C1=C(S)N=NN1C1=CC=C(O)C=C1O ZSZIANUMRDXGDW-UHFFFAOYSA-N 0.000 claims 1
- YWKQOFDNFNMVMV-UHFFFAOYSA-N 4-[5-[7-(2-methoxyethoxy)naphthalen-1-yl]-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound C12=CC(OCCOC)=CC=C2C=CC=C1C1=C(S)N=NN1C1=CC=C(O)C=C1O YWKQOFDNFNMVMV-UHFFFAOYSA-N 0.000 claims 1
- IZQAGJHUNRYXAO-UHFFFAOYSA-N 4-cyclopropyl-6-(5-naphthalen-1-yl-4-sulfanyltriazol-1-yl)benzene-1,3-diol Chemical compound OC1=CC(O)=C(N2C(=C(S)N=N2)C=2C3=CC=CC=C3C=CC=2)C=C1C1CC1 IZQAGJHUNRYXAO-UHFFFAOYSA-N 0.000 claims 1
- SIBYHFAABFDSGD-UHFFFAOYSA-N 4-ethyl-2-methyl-6-(5-naphthalen-1-yl-4-sulfanyltriazol-1-yl)benzene-1,3-diol Chemical compound CC1=C(O)C(CC)=CC(N2C(=C(S)N=N2)C=2C3=CC=CC=C3C=CC=2)=C1O SIBYHFAABFDSGD-UHFFFAOYSA-N 0.000 claims 1
- BRBCWSPPBKTMFO-UHFFFAOYSA-N 4-ethyl-6-(4-hydroxy-5-naphthalen-1-yltriazol-1-yl)benzene-1,3-diol Chemical compound C1=C(O)C(CC)=CC(N2C(=C(O)N=N2)C=2C3=CC=CC=C3C=CC=2)=C1O BRBCWSPPBKTMFO-UHFFFAOYSA-N 0.000 claims 1
- TZPQLCILIDGDDW-UHFFFAOYSA-N 4-ethyl-6-(5-naphthalen-1-yl-4-sulfanyltriazol-1-yl)benzene-1,3-diol Chemical compound C1=C(O)C(CC)=CC(N2C(=C(S)N=N2)C=2C3=CC=CC=C3C=CC=2)=C1O TZPQLCILIDGDDW-UHFFFAOYSA-N 0.000 claims 1
- FZKGQQUXHADZST-UHFFFAOYSA-N 4-ethyl-6-[4-hydroxy-5-(1-propan-2-ylindol-3-yl)triazol-1-yl]benzene-1,3-diol Chemical compound C1=C(O)C(CC)=CC(N2C(=C(O)N=N2)C=2C3=CC=CC=C3N(C(C)C)C=2)=C1O FZKGQQUXHADZST-UHFFFAOYSA-N 0.000 claims 1
- CVBDTMVJQREUFF-UHFFFAOYSA-N 4-ethyl-6-[4-hydroxy-5-(3-methoxyphenyl)triazol-1-yl]benzene-1,3-diol Chemical compound C1=C(O)C(CC)=CC(N2C(=C(O)N=N2)C=2C=C(OC)C=CC=2)=C1O CVBDTMVJQREUFF-UHFFFAOYSA-N 0.000 claims 1
- QEOMKWZMDMJVIC-UHFFFAOYSA-N 4-ethyl-6-[4-sulfanyl-5-(1,2,3-trimethylindol-5-yl)triazol-1-yl]benzene-1,3-diol Chemical compound C1=C(O)C(CC)=CC(N2C(=C(S)N=N2)C=2C=C3C(C)=C(C)N(C)C3=CC=2)=C1O QEOMKWZMDMJVIC-UHFFFAOYSA-N 0.000 claims 1
- LDFCAQGPDVBWHQ-UHFFFAOYSA-N 4-ethyl-6-[5-(1-ethylbenzimidazol-4-yl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound C1=C(O)C(CC)=CC(N2C(=C(S)N=N2)C=2C=3N=CN(CC)C=3C=CC=2)=C1O LDFCAQGPDVBWHQ-UHFFFAOYSA-N 0.000 claims 1
- CVTVSTQFCASZBT-UHFFFAOYSA-N 4-ethyl-6-[5-(1-propan-2-ylindol-4-yl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound C1=C(O)C(CC)=CC(N2C(=C(S)N=N2)C=2C=3C=CN(C=3C=CC=2)C(C)C)=C1O CVTVSTQFCASZBT-UHFFFAOYSA-N 0.000 claims 1
- RVWKDXNMDHIMPD-UHFFFAOYSA-N 4-ethyl-6-[5-(4-methoxy-2,3-dimethylphenyl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound C1=C(O)C(CC)=CC(N2C(=C(S)N=N2)C=2C(=C(C)C(OC)=CC=2)C)=C1O RVWKDXNMDHIMPD-UHFFFAOYSA-N 0.000 claims 1
- ARONUOGNRIHKER-UHFFFAOYSA-N 4-ethyl-6-[5-(4-methoxynaphthalen-1-yl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound C1=C(O)C(CC)=CC(N2C(=C(S)N=N2)C=2C3=CC=CC=C3C(OC)=CC=2)=C1O ARONUOGNRIHKER-UHFFFAOYSA-N 0.000 claims 1
- XKZSAJXABDPACT-UHFFFAOYSA-N 4-ethyl-6-[5-(5-hydroxynaphthalen-1-yl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound C1=C(O)C(CC)=CC(N2C(=C(S)N=N2)C=2C3=CC=CC(O)=C3C=CC=2)=C1O XKZSAJXABDPACT-UHFFFAOYSA-N 0.000 claims 1
- QZFJEEUJORPXSK-UHFFFAOYSA-N 4-ethyl-6-[5-(5-methoxynaphthalen-1-yl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound C1=C(O)C(CC)=CC(N2C(=C(S)N=N2)C=2C3=CC=CC(OC)=C3C=CC=2)=C1O QZFJEEUJORPXSK-UHFFFAOYSA-N 0.000 claims 1
- WKBUWEDWYXRUBC-UHFFFAOYSA-N 4-ethyl-6-[5-(6-methoxynaphthalen-1-yl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound C1=C(O)C(CC)=CC(N2C(=C(S)N=N2)C=2C3=CC=C(OC)C=C3C=CC=2)=C1O WKBUWEDWYXRUBC-UHFFFAOYSA-N 0.000 claims 1
- SYGCUBZSIBCWCY-UHFFFAOYSA-N 4-ethyl-6-[5-(7-methoxy-1-propan-2-ylindol-4-yl)-4-sulfanyltriazol-1-yl]benzene-1,3-diol Chemical compound C1=C(O)C(CC)=CC(N2C(=C(S)N=N2)C=2C=3C=CN(C=3C(OC)=CC=2)C(C)C)=C1O SYGCUBZSIBCWCY-UHFFFAOYSA-N 0.000 claims 1
- MWOXTTWWXHPMFD-UHFFFAOYSA-N 4-hexyl-6-(5-naphthalen-1-yl-4-sulfanyltriazol-1-yl)benzene-1,3-diol Chemical compound C1=C(O)C(CCCCCC)=CC(N2C(=C(S)N=N2)C=2C3=CC=CC=C3C=CC=2)=C1O MWOXTTWWXHPMFD-UHFFFAOYSA-N 0.000 claims 1
- KDKQKMXAQNXMCH-UHFFFAOYSA-N 4-methoxy-6-(5-naphthalen-1-yl-4-sulfanyltriazol-1-yl)benzene-1,3-diol Chemical compound C1=C(O)C(OC)=CC(N2C(=C(S)N=N2)C=2C3=CC=CC=C3C=CC=2)=C1O KDKQKMXAQNXMCH-UHFFFAOYSA-N 0.000 claims 1
- OQUKZUYJPMHMOY-UHFFFAOYSA-N 4-methyl-6-(5-naphthalen-1-yl-4-sulfanyltriazol-1-yl)benzene-1,3-diol Chemical compound C1=C(O)C(C)=CC(N2C(=C(S)N=N2)C=2C3=CC=CC=C3C=CC=2)=C1O OQUKZUYJPMHMOY-UHFFFAOYSA-N 0.000 claims 1
- SQZZKFZAZWVZQA-UHFFFAOYSA-N 4-tert-butyl-6-(5-naphthalen-1-yl-4-sulfanyltriazol-1-yl)benzene-1,3-diol Chemical compound C1=C(O)C(C(C)(C)C)=CC(N2C(=C(S)N=N2)C=2C3=CC=CC=C3C=CC=2)=C1O SQZZKFZAZWVZQA-UHFFFAOYSA-N 0.000 claims 1
- XUXKEJCQZXTDGA-UHFFFAOYSA-N 5-(2-hydroxyethoxy)-2-(5-naphthalen-1-yl-4-sulfanyltriazol-1-yl)phenol Chemical compound OC1=CC(OCCO)=CC=C1N1C(C=2C3=CC=CC=C3C=CC=2)=C(S)N=N1 XUXKEJCQZXTDGA-UHFFFAOYSA-N 0.000 claims 1
- CEQSWLOPWAOKAX-UHFFFAOYSA-N 5-(5-naphthalen-1-yl-4-sulfanyltriazol-1-yl)benzene-1,2,4-triol Chemical compound C1=C(O)C(O)=CC(O)=C1N1C(C=2C3=CC=CC=C3C=CC=2)=C(S)N=N1 CEQSWLOPWAOKAX-UHFFFAOYSA-N 0.000 claims 1
- AKVDFVRIPGIRTJ-UHFFFAOYSA-N 5-(methoxymethoxy)-2-(5-naphthalen-1-yl-4-sulfanyltriazol-1-yl)phenol Chemical compound OC1=C(C=CC(=C1)OCOC)N1N=NC(=C1C1=CC=CC2=CC=CC=C12)S AKVDFVRIPGIRTJ-UHFFFAOYSA-N 0.000 claims 1
- YLZSIJWVVKNVOF-UHFFFAOYSA-N 5-fluoro-2-(5-naphthalen-1-yl-4-sulfanyltriazol-1-yl)phenol Chemical compound OC1=CC(F)=CC=C1N1C(C=2C3=CC=CC=C3C=CC=2)=C(S)N=N1 YLZSIJWVVKNVOF-UHFFFAOYSA-N 0.000 claims 1
- BJUJVKCQFAZWNZ-UHFFFAOYSA-N 5-fluoro-6-hydroxy-3-(5-naphthalen-1-yl-4-sulfanyltriazol-1-yl)-1h-pyridin-2-one Chemical compound C1=C(F)C(O)=NC(O)=C1N1C(C=2C3=CC=CC=C3C=CC=2)=C(S)N=N1 BJUJVKCQFAZWNZ-UHFFFAOYSA-N 0.000 claims 1
- IGRZOLAVLPYOHI-UHFFFAOYSA-N 5-methyl-4-(5-naphthalen-1-yl-4-sulfanyltriazol-1-yl)benzene-1,3-diol Chemical compound CC1=CC(O)=CC(O)=C1N1C(C=2C3=CC=CC=C3C=CC=2)=C(S)N=N1 IGRZOLAVLPYOHI-UHFFFAOYSA-N 0.000 claims 1
- DMELTCUPFOACNM-UHFFFAOYSA-N Cc1cc(O)c(C)c(O)c1-n1nnc(c1S)-c1cccc2ccccc12 Chemical compound Cc1cc(O)c(C)c(O)c1-n1nnc(c1S)-c1cccc2ccccc12 DMELTCUPFOACNM-UHFFFAOYSA-N 0.000 claims 1
- RVAQIUULWULRNW-UHFFFAOYSA-N Ganetespib Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(O)=NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O RVAQIUULWULRNW-UHFFFAOYSA-N 0.000 claims 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 claims 1
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 claims 1
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 claims 1
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 claims 1
- IMIRMEJSUFZWKU-UHFFFAOYSA-N [1-(2,4-dihydroxy-5-methoxyphenyl)-5-(3-propan-2-yloxyphenyl)triazol-4-yl] sulfamate Chemical compound C1=C(O)C(OC)=CC(N2C(=C(OS(N)(=O)=O)N=N2)C=2C=C(OC(C)C)C=CC=2)=C1O IMIRMEJSUFZWKU-UHFFFAOYSA-N 0.000 claims 1
- BRNIYUYGNXFNDX-UHFFFAOYSA-N [1-(2,4-dihydroxy-5-methoxyphenyl)-5-(3-propan-2-ylphenyl)triazol-4-yl]carbamothioic s-acid Chemical compound C1=C(O)C(OC)=CC(N2C(=C(NC(O)=S)N=N2)C=2C=C(C=CC=2)C(C)C)=C1O BRNIYUYGNXFNDX-UHFFFAOYSA-N 0.000 claims 1
- IQDVVWULTHZRAS-UHFFFAOYSA-N [1-(2,4-dihydroxy-5-methoxyphenyl)-5-(8-methoxyquinolin-5-yl)triazol-4-yl] carbamate Chemical compound C1=C(O)C(OC)=CC(N2C(=C(OC(N)=O)N=N2)C=2C3=CC=CN=C3C(OC)=CC=2)=C1O IQDVVWULTHZRAS-UHFFFAOYSA-N 0.000 claims 1
- RJRXGTWAIDQXOO-UHFFFAOYSA-N [1-(2,4-dihydroxy-5-methoxyphenyl)-5-naphthalen-1-yltriazol-4-yl] carbamate Chemical compound C1=C(O)C(OC)=CC(N2C(=C(OC(N)=O)N=N2)C=2C3=CC=CC=C3C=CC=2)=C1O RJRXGTWAIDQXOO-UHFFFAOYSA-N 0.000 claims 1
- LYICTQRFSTZNTC-UHFFFAOYSA-N [1-(2,4-dihydroxy-5-methoxyphenyl)-5-naphthalen-1-yltriazol-4-yl] sulfamate Chemical compound C1=C(O)C(OC)=CC(N2C(=C(OS(N)(=O)=O)N=N2)C=2C3=CC=CC=C3C=CC=2)=C1O LYICTQRFSTZNTC-UHFFFAOYSA-N 0.000 claims 1
- GYLOFNZVTKALOR-UHFFFAOYSA-N [1-(2,4-dihydroxy-5-methoxyphenyl)-5-naphthalen-1-yltriazol-4-yl]urea Chemical compound C1=C(O)C(OC)=CC(N2C(=C(NC(N)=O)N=N2)C=2C3=CC=CC=C3C=CC=2)=C1O GYLOFNZVTKALOR-UHFFFAOYSA-N 0.000 claims 1
- FPSHBUWKMHVLCF-UHFFFAOYSA-N [1-(2,4-dihydroxy-5-propan-2-ylphenyl)-5-(3-methylquinolin-5-yl)triazol-4-yl]carbamic acid Chemical compound C1=C(O)C(C(C)C)=CC(N2C(=C(NC(O)=O)N=N2)C=2C3=CC(C)=CN=C3C=CC=2)=C1O FPSHBUWKMHVLCF-UHFFFAOYSA-N 0.000 claims 1
- LTBDTMUWZOTWTQ-UHFFFAOYSA-N [1-(5-ethyl-2,4-dihydroxyphenyl)-5-(1-methylindol-4-yl)triazol-4-yl] carbamate Chemical compound C1=C(O)C(CC)=CC(N2C(=C(OC(N)=O)N=N2)C=2C=3C=CN(C)C=3C=CC=2)=C1O LTBDTMUWZOTWTQ-UHFFFAOYSA-N 0.000 claims 1
- RVRQAFGBWUTVLH-UHFFFAOYSA-N [1-(5-ethyl-2,4-dihydroxyphenyl)-5-[3-(trifluoromethyl)phenyl]triazol-4-yl] carbamate Chemical compound C1=C(O)C(CC)=CC(N2C(=C(OC(N)=O)N=N2)C=2C=C(C=CC=2)C(F)(F)F)=C1O RVRQAFGBWUTVLH-UHFFFAOYSA-N 0.000 claims 1
- BOCUSNZXZUAVOK-UHFFFAOYSA-N [1-(5-ethyl-2,4-dihydroxyphenyl)-5-quinolin-5-yltriazol-4-yl]urea Chemical compound C1=C(O)C(CC)=CC(N2C(=C(NC(N)=O)N=N2)C=2C3=CC=CN=C3C=CC=2)=C1O BOCUSNZXZUAVOK-UHFFFAOYSA-N 0.000 claims 1
- WPVXHUIQQMIINB-UHFFFAOYSA-N [3-[3-(2,4-dihydroxyphenyl)-5-sulfanyltriazol-4-yl]phenyl]-phenylmethanone Chemical compound OC1=CC(O)=CC=C1N1C(C=2C=C(C=CC=2)C(=O)C=2C=CC=CC=2)=C(S)N=N1 WPVXHUIQQMIINB-UHFFFAOYSA-N 0.000 claims 1
- TVALEMZQUFNARM-UHFFFAOYSA-N [5-(2,3-difluorophenyl)-1-(2,4-dihydroxy-5-methoxyphenyl)triazol-4-yl]urea Chemical compound C1=C(O)C(OC)=CC(N2C(=C(NC(N)=O)N=N2)C=2C(=C(F)C=CC=2)F)=C1O TVALEMZQUFNARM-UHFFFAOYSA-N 0.000 claims 1
- MADWYBTXVLAGGQ-UHFFFAOYSA-N [5-(2-chloro-1-methylindol-4-yl)-1-(2,4-dihydroxyphenyl)triazol-4-yl] carbamate Chemical compound C1=CC=C2N(C)C(Cl)=CC2=C1C1=C(OC(N)=O)N=NN1C1=CC=C(O)C=C1O MADWYBTXVLAGGQ-UHFFFAOYSA-N 0.000 claims 1
- PGCHQRBMMBTTDM-UHFFFAOYSA-N [5-[3,5-bis(trifluoromethyl)phenyl]-1-(2,4-dihydroxy-5-methoxyphenyl)triazol-4-yl] carbamate Chemical compound C1=C(O)C(OC)=CC(N2C(=C(OC(N)=O)N=N2)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)=C1O PGCHQRBMMBTTDM-UHFFFAOYSA-N 0.000 claims 1
- IYEHPIZSXOBJLY-UHFFFAOYSA-N [Na].[Na].CCc1cc(-c2nnc(S)n2-c2ccc(OC)c3n(ccc23)C(C)C)c(O)cc1O Chemical compound [Na].[Na].CCc1cc(-c2nnc(S)n2-c2ccc(OC)c3n(ccc23)C(C)C)c(O)cc1O IYEHPIZSXOBJLY-UHFFFAOYSA-N 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000005605 benzo group Chemical group 0.000 claims 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 claims 1
- 125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 claims 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 125000005322 morpholin-1-yl group Chemical group 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 125000005888 tetrahydroindolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62897904P | 2004-11-18 | 2004-11-18 | |
| US60/628,979 | 2004-11-18 | ||
| US70935805P | 2005-08-18 | 2005-08-18 | |
| US60/709,358 | 2005-08-18 | ||
| US72504405P | 2005-10-06 | 2005-10-06 | |
| US60/725,044 | 2005-10-06 | ||
| PCT/US2005/041779 WO2006055760A1 (en) | 2004-11-18 | 2005-11-17 | Triazole compounds that modulate hsp90 activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008520702A JP2008520702A (ja) | 2008-06-19 |
| JP2008520702A5 true JP2008520702A5 (enExample) | 2009-01-08 |
| JP4954083B2 JP4954083B2 (ja) | 2012-06-13 |
Family
ID=35966006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007543263A Expired - Fee Related JP4954083B2 (ja) | 2004-11-18 | 2005-11-17 | Ｈｓｐ９０活性を調節するトリアゾール化合物 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US7825148B2 (enExample) |
| EP (3) | EP2298748B1 (enExample) |
| JP (1) | JP4954083B2 (enExample) |
| KR (2) | KR20140006070A (enExample) |
| CN (2) | CN101072759B (enExample) |
| AU (1) | AU2005306484C1 (enExample) |
| BR (1) | BRPI0518315B8 (enExample) |
| CA (1) | CA2586612C (enExample) |
| DK (1) | DK1817295T3 (enExample) |
| ES (2) | ES2594874T3 (enExample) |
| HR (1) | HRP20130095T1 (enExample) |
| IL (1) | IL183108A (enExample) |
| ME (1) | ME01498B (enExample) |
| MX (1) | MX2007005940A (enExample) |
| NZ (1) | NZ555158A (enExample) |
| PL (1) | PL1817295T3 (enExample) |
| PT (1) | PT1817295E (enExample) |
| RS (1) | RS52642B (enExample) |
| TW (1) | TWI380983B (enExample) |
| WO (1) | WO2006055760A1 (enExample) |
Families Citing this family (112)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2005063222A1 (ja) * | 2003-12-26 | 2007-07-19 | 協和醗酵工業株式会社 | Ｈｓｐ９０ファミリー蛋白質阻害剤 |
| KR20140006070A (ko) * | 2004-11-18 | 2014-01-15 | 신타 파마슈티칼스 코프. | Ｈｓｐ90 활성을 조절하는 트리아졸 화합물 |
| DE102005007304A1 (de) | 2005-02-17 | 2006-08-24 | Merck Patent Gmbh | Triazolderivate |
| RU2007137133A (ru) * | 2005-03-09 | 2009-04-20 | Ниппон Каяку Кабусики Кайся (Jp) | Новый ингибитор hsp90 |
| US8399464B2 (en) | 2005-03-09 | 2013-03-19 | Nippon Kayaku Kabushiki Kaisha | HSP90 inhibitor |
| CA2604042C (en) | 2005-04-13 | 2016-06-21 | Astex Therapeutics Limited | Pharmaceutical compounds |
| EP1934185A1 (en) | 2005-08-12 | 2008-06-25 | Synta Pharmaceuticals Corporation | Pyrazole compounds that modulate hsp90 activity |
| US8629285B2 (en) | 2005-08-18 | 2014-01-14 | Synta Pharmaceuticals Corp. | Imidazole compounds that modulate HSP90 activity |
| CA2618628C (en) | 2005-08-18 | 2014-11-18 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| US7754725B2 (en) | 2006-03-01 | 2010-07-13 | Astex Therapeutics Ltd. | Dihydroxyphenyl isoindolymethanones |
| WO2007111211A1 (ja) | 2006-03-28 | 2007-10-04 | Nippon Kayaku Kabushiki Kaisha | タキサン類の高分子結合体 |
| US20070250391A1 (en) * | 2006-04-05 | 2007-10-25 | Prade Hendrik D | Merchandising system and method for food and non-food items for a meal kit |
| US8940332B2 (en) | 2006-05-18 | 2015-01-27 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of podophyllotoxins |
| WO2007139952A2 (en) * | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Method for the preparation of triazole compounds with hsp90 modulating activity |
| CA2653217A1 (en) | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders associated with protooncogene products |
| CA2653222A1 (en) * | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| US8063083B2 (en) | 2006-05-25 | 2011-11-22 | Synta Pharmaceuticals Corp. | Method for treating non-Hodgkin's lymphoma |
| CA2653327A1 (en) * | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Compounds that modulate hsp90 activity and methods for identifying same |
| AU2007267860B2 (en) * | 2006-05-25 | 2012-08-09 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate Hsp90 activity |
| EP2035396B1 (en) | 2006-05-25 | 2014-05-14 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| AU2012200157B2 (en) * | 2006-05-25 | 2014-08-21 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders associated with protooncogene products |
| JP5480623B2 (ja) * | 2006-08-17 | 2014-04-23 | シンタ ファーマシューティカルズ コーポレーション | Ｈｓｐ９０活性を調節するトリアゾール化合物 |
| CA2664852A1 (en) * | 2006-10-03 | 2008-04-10 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of resorcinol derivatives |
| EP2073804B1 (en) | 2006-10-12 | 2017-09-13 | Astex Therapeutics Limited | Hydroxy-substituted benzoic acid amide compounds for use in the treatment of pain |
| US8916552B2 (en) | 2006-10-12 | 2014-12-23 | Astex Therapeutics Limited | Pharmaceutical combinations |
| GB0620259D0 (en) * | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| JP5528807B2 (ja) | 2006-10-12 | 2014-06-25 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
| WO2008051416A2 (en) * | 2006-10-19 | 2008-05-02 | Synta Pharmaceuticals Corp. | Compounds that inhibit the activity of hsp90 for treating infections |
| FR2907453B1 (fr) | 2006-10-24 | 2008-12-26 | Sanofi Aventis Sa | Nouveaux derives du fluorene,compositions les contenant et utilisation |
| WO2008057246A2 (en) * | 2006-10-26 | 2008-05-15 | Synta Pharmaceuticals Corp. | Method for treating inflammatory disorders |
| US8334364B2 (en) | 2006-11-06 | 2012-12-18 | Nipon Kayaku Kabushiki Kaisha | High-molecular weight derivative of nucleic acid antimetabolite |
| EP2090607B1 (en) | 2006-11-08 | 2015-05-20 | Nippon Kayaku Kabushiki Kaisha | Polymeric derivative of nucleic acid metabolic antagonist |
| DE102007002715A1 (de) * | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | Triazolderivat |
| CA2677481C (en) * | 2007-02-08 | 2015-07-07 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| TW200904417A (en) * | 2007-02-20 | 2009-02-01 | Synta Pharmaceuticals Corp | Triazole compounds that modulate Hsp90 activity |
| US8993608B2 (en) * | 2007-03-12 | 2015-03-31 | Synta Pharmaceuticals Corp. | Method for inhibiting topoisomerase II |
| WO2008153730A2 (en) * | 2007-05-25 | 2008-12-18 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders associated with mutations in c-met |
| CN101801983B (zh) * | 2007-08-13 | 2014-01-29 | 辛塔制药公司 | 调控hsp90活性的三唑化合物 |
| WO2009041570A1 (ja) | 2007-09-28 | 2009-04-02 | Nippon Kayaku Kabushiki Kaisha | ステロイド類の高分子結合体 |
| ATE538105T1 (de) | 2007-10-12 | 2012-01-15 | Arqule Inc | Substituierte tetrazolverbindungen und ihre verwendung |
| GB0722680D0 (en) * | 2007-11-19 | 2007-12-27 | Topotarget As | Therapeutic compounds and their use |
| KR100947696B1 (ko) * | 2007-11-23 | 2010-03-16 | 재단법인서울대학교산학협력재단 | 1,2,4-트리아졸 유도체를 함유하는 Ｈｓｐ９０ 억제제 및이를 이용한 항암제 |
| NZ587165A (en) * | 2008-02-04 | 2012-03-30 | Mercury Therapeutics Inc | Ampk modulators |
| FR2928645A1 (fr) * | 2008-03-14 | 2009-09-18 | Sanofi Aventis Sa | Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation |
| CN101977631A (zh) | 2008-03-18 | 2011-02-16 | 日本化药株式会社 | 生理活性物质的高分子量偶联物 |
| US9149540B2 (en) | 2008-05-08 | 2015-10-06 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of folic acid or folic acid derivative |
| WO2009139916A1 (en) * | 2008-05-16 | 2009-11-19 | Synta Pharmaceuticals Corp. | Tricyclic triazole compounds that modulate hsp90 activity |
| US8450500B2 (en) | 2008-06-04 | 2013-05-28 | Synta Pharmaceuticals Corp. | Pyrrole compounds that modulate HSP90 activity |
| WO2009158026A1 (en) | 2008-06-27 | 2009-12-30 | Synta Pharmaceuticals Corp. | Hydrazonamide compounds that modulate hsp90 activity |
| ES2415234T3 (es) | 2008-08-08 | 2013-07-24 | Synta Pharmaceuticals Corp. | Compuestos de triazol que modulan la actividad Hsp90 |
| WO2010017545A2 (en) * | 2008-08-08 | 2010-02-11 | Synta Pharamceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| WO2010131675A1 (ja) | 2009-05-15 | 2010-11-18 | 日本化薬株式会社 | 水酸基を有する生理活性物質の高分子結合体 |
| AR077405A1 (es) * | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
| FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
| AU2010308306A1 (en) | 2009-10-19 | 2012-05-10 | Synta Pharmaceuticals Corp. | Combination cancer therapy with HSP90 inhibitory compounds |
| US20130156755A1 (en) * | 2010-04-19 | 2013-06-20 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor |
| EP2560640A1 (en) | 2010-04-19 | 2013-02-27 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor |
| US20130172333A1 (en) | 2010-05-20 | 2013-07-04 | Synta Pharmaceuticals Corp. | Formulation and dosing of hsp90 inhibitory compounds |
| AU2011255438A1 (en) | 2010-05-20 | 2013-01-10 | Synta Pharmaceuticals Corp. | Method of treating lung adenocarcinoma with Hsp90 inhibitory compounds |
| WO2011149824A1 (en) | 2010-05-24 | 2011-12-01 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor |
| WO2012026433A1 (ja) * | 2010-08-23 | 2012-03-01 | 第一三共株式会社 | 三環性ピラゾロピリミジン誘導体のフリー体結晶 |
| WO2012037072A1 (en) | 2010-09-13 | 2012-03-22 | Synta Pharmaceuticals Corporation | Hsp90 inhibitors for treating non-small cell lung cancers in wild-type egfr and/or kras patients |
| US9018323B2 (en) | 2010-11-17 | 2015-04-28 | Nippon Kayaku Kabushiki Kaisha | Polymer derivative of cytidine metabolic antagonist |
| CN103327976A (zh) | 2010-11-18 | 2013-09-25 | 辛塔医药品有限公司 | 基于缺氧状态预选受试者以用于治疗性治疗 |
| EP2640384A1 (en) | 2010-11-18 | 2013-09-25 | Synta Pharmaceuticals Corp. | Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status |
| US20140005145A1 (en) * | 2010-12-08 | 2014-01-02 | Synta Pharmaceuticals Corp. | Combination breast cancer therapy with hsp90 inhibitory compounds |
| EP2655345B1 (en) | 2010-12-20 | 2015-02-18 | SIGMA-TAU Research Switzerland S.A. | Aryl triazole compounds with antitumoural activity |
| WO2012096919A1 (en) * | 2011-01-11 | 2012-07-19 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors |
| EP2678013A1 (en) * | 2011-02-23 | 2014-01-01 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with radiotherapy |
| JP2014507443A (ja) * | 2011-02-24 | 2014-03-27 | シンタ ファーマシューティカルズ コーポレーション | Ｈｓｐ９０阻害化合物での前立腺癌治療 |
| WO2012116247A1 (en) | 2011-02-25 | 2012-08-30 | Synta Pharmaceuticals Corp. | Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers |
| US20140228418A1 (en) * | 2011-05-23 | 2014-08-14 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with mek inhibitors |
| US20140315943A1 (en) * | 2011-05-24 | 2014-10-23 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with mtor/p13k inhibitors |
| US20140194388A1 (en) * | 2011-05-26 | 2014-07-10 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with chk inhibitors |
| AU2012280931A1 (en) | 2011-07-07 | 2014-02-27 | Synta Pharmaceuticals Corp. | Treating cancer with HSP90 inhibitory compounds |
| US20140296176A1 (en) * | 2011-08-19 | 2014-10-02 | Synta Pharmaceuticals Corp. | Combination cancer therapy with an hsp90 inhibitor and an antimetabolite |
| EP2754682B1 (en) | 2011-09-11 | 2017-06-07 | Nippon Kayaku Kabushiki Kaisha | Method for manufacturing block copolymer |
| JP2014534228A (ja) * | 2011-11-02 | 2014-12-18 | シンタ ファーマシューティカルズ コーポレーション | 白金含有剤とｈｓｐ９０阻害剤の組合せ療法 |
| WO2013067162A1 (en) | 2011-11-02 | 2013-05-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
| CA2854188A1 (en) | 2011-11-14 | 2013-05-23 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with braf inhibitors |
| WO2013148857A1 (en) * | 2012-03-28 | 2013-10-03 | Synta Pharmaceuticals Corp. | Triazole derivatives as hsp90 inhibitors |
| US20140079636A1 (en) | 2012-04-16 | 2014-03-20 | Dinesh U. Chimmanamada | Targeted therapeutics |
| CA2871540A1 (en) | 2012-05-10 | 2013-11-14 | Synta Pharmaceuticals Corp. | Treating cancer with hsp90 inhibitory compounds |
| EP2887804B1 (en) | 2012-05-22 | 2021-01-27 | Trustees of Dartmouth College | Cycloalkanyl[b]indoles useful as glp-1 modulators |
| AU2013331070A1 (en) * | 2012-10-19 | 2015-05-07 | Synta Pharmaceuticals Corp. | Treating polycystic kidney disease with HSP90 inhibitory compounds |
| WO2015038649A1 (en) | 2013-09-10 | 2015-03-19 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
| WO2015066053A2 (en) * | 2013-10-28 | 2015-05-07 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
| EP3129064B1 (en) | 2014-03-03 | 2020-01-01 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics |
| WO2015167211A1 (ko) * | 2014-04-30 | 2015-11-05 | 경북대학교 산학협력단 | 3-아릴-1,2,4-트라이아졸 유도체 및 이의 용도 |
| KR101711732B1 (ko) * | 2014-04-30 | 2017-03-02 | 경북대학교 산학협력단 | 3-아릴-1,2,4-트라이아졸 유도체 및 이의 용도 |
| US20170231986A1 (en) | 2014-08-11 | 2017-08-17 | Acerta Pharma B.V. | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor |
| US20170224819A1 (en) | 2014-08-11 | 2017-08-10 | Acerta Pharma B.V. | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor |
| EP3179992B1 (en) | 2014-08-11 | 2022-05-11 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor |
| US10035792B2 (en) * | 2015-01-22 | 2018-07-31 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Resorcinol derivative as HSP90 inhibitor |
| BR112017016973A2 (pt) | 2015-02-09 | 2018-04-03 | Synta Pharmaceuticals Corp. | terapia de combinação de inibidores de hsp90 e inibidores de pd-1 para tratamento de câncer |
| TN2017000483A1 (en) | 2015-05-20 | 2019-04-12 | Amgen Inc | Triazole agonists of the apj receptor. |
| CN106349233B (zh) * | 2015-07-15 | 2021-06-01 | 上海翰森生物医药科技有限公司 | 3,4-二苯基-4h-1,2,4-三唑衍生物及其制备方法和应用 |
| EP3380970B1 (en) | 2015-11-24 | 2023-01-04 | Sanford Burnham Prebys Medical Discovery Institute | Novel azole derivatives as apelin receptor agonist |
| CN108697666A (zh) | 2016-02-29 | 2018-10-23 | 辛塔制药公司 | 用于治疗卵巢癌的组合疗法 |
| WO2017192485A1 (en) | 2016-05-03 | 2017-11-09 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the apj receptor |
| US10906890B2 (en) | 2016-11-16 | 2021-02-02 | Amgen Inc. | Triazole phenyl compounds as agonists of the APJ receptor |
| WO2018097945A1 (en) | 2016-11-16 | 2018-05-31 | Amgen Inc. | Heteroaryl-substituted triazoles as apj receptor agonists |
| US11191762B2 (en) | 2016-11-16 | 2021-12-07 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the APJ Receptor |
| EP3541792B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole furan compounds as agonists of the apj receptor |
| WO2018093580A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Triazole pyridyl compounds as agonists of the apj receptor |
| MA46827A (fr) | 2016-11-16 | 2019-09-25 | Amgen Inc | Composés de triazole à substitution cycloalkyle en tant qu'agonistes du récepteur apj |
| CN111875583B (zh) * | 2017-10-17 | 2021-06-15 | 中国科学院上海药物研究所 | 三氮唑衍生物及其制备方法和用途 |
| WO2019089335A1 (en) | 2017-11-03 | 2019-05-09 | Amgen Inc. | Fused triazole agonists of the apj receptor |
| WO2019213006A1 (en) | 2018-05-01 | 2019-11-07 | Amgen Inc. | Substituted pyrimidinones as agonists of the apj receptor |
| EP3653611A1 (en) * | 2018-11-15 | 2020-05-20 | Centre National De La Recherche Scientifique | Inhibitors of metallo-beta-lactamases |
| CN113874015B (zh) | 2018-12-21 | 2024-05-24 | 细胞基因公司 | Ripk2的噻吩并吡啶抑制剂 |
| US20220184217A1 (en) * | 2019-04-03 | 2022-06-16 | Tarveda Therapeutics, Inc. | Hsp90-binding conjugates and formulations thereof |
Family Cites Families (133)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB928919A (en) | 1960-08-16 | 1963-06-19 | Bellon Labor Sa Roger | Triazole derivatives and a process for their preparation |
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4178253A (en) | 1977-04-05 | 1979-12-11 | Ciba-Geigy Corporation | Corrosion inhibited lubricant compositions |
| US4269846A (en) | 1979-10-29 | 1981-05-26 | Usv Pharmaceutical Corporation | Heterocyclic compounds useful as anti-allergy agents |
| JPS5770820A (en) | 1980-10-20 | 1982-05-01 | Haruo Ogura | Immunoregulating agent |
| JPS5910574A (ja) | 1982-07-07 | 1984-01-20 | Fujisawa Pharmaceut Co Ltd | トリアゾ−ル誘導体およびその製造法 |
| FR2546887B1 (fr) | 1983-05-30 | 1985-08-30 | Paris 7 Universite | Procede de preparation de dihydro-2,4 triazol-1,2,4 thiones-3 disubstituees en positions 4 et 5 et nouveaux composes pouvant etre prepares par ce procede |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US4624995A (en) | 1985-04-09 | 1986-11-25 | Minnesota Mining And Manufacturing Company | Triazolinethione-containing polymer |
| US4740568A (en) | 1985-04-09 | 1988-04-26 | Minnesota Mining And Manufacturing Company | Triazolinethione-containing polymer |
| US5436252A (en) | 1986-12-19 | 1995-07-25 | Merrell Dow Pharmaceuticals Inc. | 5-aryl-3H-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders |
| US5006650A (en) | 1987-02-11 | 1991-04-09 | The Upjohn Company | Novel N-1 substituted beta-lactams as antibiotics |
| DE3729070A1 (de) | 1987-09-01 | 1989-03-09 | Bayer Ag | Substituierte triazolinone |
| US5241074A (en) | 1988-05-09 | 1993-08-31 | Bayer Aktiengesellschaft | Sulphonylaminocarbonyltriazolinones |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5219722A (en) | 1990-09-21 | 1993-06-15 | Konica Corporation | Silver halide color photographic light-sensitive material |
| SK278998B6 (sk) | 1991-02-01 | 1998-05-06 | Merck Sharp & Dohme Limited | Deriváty imidazolu, triazolu a tetrazolu, spôsob i |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| ATE205202T1 (de) | 1992-03-13 | 2001-09-15 | Merck Sharp & Dohme | Imidazol-, triazol- und tetrazolderivate |
| TW218017B (enExample) | 1992-04-28 | 1993-12-21 | Takeda Pharm Industry Co Ltd | |
| DE4222771A1 (de) | 1992-07-10 | 1994-01-13 | Bayer Ag | Heterocyclyltriazolinone |
| DE4234801A1 (de) | 1992-10-15 | 1994-04-21 | Bayer Ag | Sulfonylaminocarbonyltriazolinone |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| DE4303376A1 (de) | 1993-02-05 | 1994-08-11 | Bayer Ag | Substituierte Triazolinone |
| DE4303676A1 (de) | 1993-02-09 | 1994-08-11 | Bayer Ag | 1-Aryltriazolin(thi)one |
| DE4411913A1 (de) | 1994-04-07 | 1995-10-12 | Bayer Ag | Substituierte Sulfonylaminocarbonyltriazolinone |
| US5538988A (en) | 1994-04-26 | 1996-07-23 | Martinez; Gregory R. | Benzocycloalkylazolethione derivatives |
| US5489598A (en) | 1994-06-08 | 1996-02-06 | Warner-Lambert Company | Cytoprotection utilizing aryltriazol-3-thiones |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| JP3372365B2 (ja) | 1994-08-19 | 2003-02-04 | 富士写真フイルム株式会社 | ハロゲン化銀写真感光材料およびそれを用いた画像形成方法 |
| DE19502579A1 (de) | 1995-01-27 | 1996-08-01 | Bayer Ag | Sulfonylamino(thio)carbonyl-triazolin(thi)one |
| US6080772A (en) | 1995-06-07 | 2000-06-27 | Sugen, Inc. | Thiazole compounds and methods of modulating signal transduction |
| DE19521162A1 (de) | 1995-06-09 | 1996-12-12 | Bayer Ag | N-Aryl-1,2,4-triazolin-5-one |
| DE19525162A1 (de) | 1995-07-11 | 1997-01-16 | Bayer Ag | Sulfonylamino(thio)carbonylverbindungen |
| AU6517196A (en) | 1995-07-13 | 1997-02-10 | Knoll Aktiengesellschaft | Piperazine derivatives as therapeutic agents |
| DE19540737A1 (de) | 1995-11-02 | 1997-05-07 | Bayer Ag | Substituierte Sulfonylamino(thio)carbonylverbindungen |
| DE19609059A1 (de) | 1996-03-08 | 1997-09-11 | Bayer Ag | Substituierte Arylsulfonylamino(thio)carbonyl-triazolin(thi)one |
| US6274171B1 (en) | 1996-03-25 | 2001-08-14 | American Home Products Corporation | Extended release formulation of venlafaxine hydrochloride |
| ZA974703B (en) | 1996-05-30 | 1997-12-30 | Bayer Ag | Substituted sulfonylamino(thio)carbonyl compounds. |
| TW467902B (en) | 1996-07-31 | 2001-12-11 | Bristol Myers Squibb Co | Diphenyl heterocycles as potassium channel modulators |
| DE19632945A1 (de) | 1996-08-16 | 1998-02-19 | Bayer Ag | Substituierte Sulfonylamino(thio)carbonylverbindungen |
| EP0938487A2 (en) | 1996-11-12 | 1999-09-01 | Sepracor, Inc. | 2$i(R),4$i(S),$i(R),$i(S)- AND 2$i(S),4$i(R),$i(R),$i(S)-HYDROXYITRACONAZOLE- AND HYDROXYSAPERCONAZOLE DERIVATIVES |
| US5968921A (en) | 1997-10-24 | 1999-10-19 | Orgegon Health Sciences University | Compositions and methods for promoting nerve regeneration |
| JP3788676B2 (ja) * | 1997-11-11 | 2006-06-21 | 富士写真フイルム株式会社 | 有機エレクトロルミネツセンス素子材料およびそれを使用した有機エレクトロルミネツセンス素子 |
| AU3254099A (en) | 1998-03-09 | 1999-09-27 | Basf Aktiengesellschaft | Hetaryl-substituted benzyl phenyl ethers, method for the production thereof, andtheir use for combating harmful fungi and animal pests |
| US6185567B1 (en) * | 1998-05-29 | 2001-02-06 | The Trustees Of The University Of Pennsylvania | Authenticated access to internet based research and data services |
| IT1302034B1 (it) * | 1998-08-31 | 2000-07-20 | Enirisorse Spa | Catalizzatori superacidi solidi per l'isomerizzazione di idrocarburi eprocedimento sol-gel per il loro ottenimento |
| JP2000100570A (ja) | 1998-09-25 | 2000-04-07 | Toray Ind Inc | 発光素子 |
| JP2000284412A (ja) | 1999-03-30 | 2000-10-13 | Fuji Photo Film Co Ltd | 熱現像写真材料 |
| US6492406B1 (en) | 1999-05-21 | 2002-12-10 | Astrazeneca Ab | Pharmaceutically active compounds |
| US20040110684A1 (en) | 1999-08-02 | 2004-06-10 | Universite Catholique De Louvain | Novel pharmaceutical compositions for modulating angiogenesis |
| CA2429196A1 (en) | 2000-03-24 | 2001-10-04 | Duke University | Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto |
| EP1293503A4 (en) | 2000-05-19 | 2008-04-02 | Astellas Pharma Inc | Triazole derivatives |
| US20030216385A1 (en) | 2000-05-19 | 2003-11-20 | Takahiko Tobe | Triazole derivatives |
| WO2002002123A1 (en) | 2000-06-29 | 2002-01-10 | Trustees Of Boston University | Use of geldanamycin and related compounds for prophylaxis or treatment of fibrogenic disorders |
| KR20030046397A (ko) | 2000-07-28 | 2003-06-12 | 슬로안-케테링인스티튜트퍼캔서리서치 | 세포증식성 질환 및 바이러스 감염의 치료 방법 |
| AU2877202A (en) | 2000-11-02 | 2002-05-15 | Sloan Kettering Inst Cancer | Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors |
| WO2002066447A1 (en) | 2001-02-21 | 2002-08-29 | Ono Pharmaceutical Co., Ltd. | 4h-1,2,4-triazole-3(2h)-thione deratives as sphingomyelinase inhibitors |
| US20060079493A1 (en) | 2001-03-01 | 2006-04-13 | Lawrence Fritz | Methods for treating genetically- defined proliferative disorders with hsp90 inhibitors |
| US20040235813A1 (en) | 2001-05-03 | 2004-11-25 | Erich Wanker | Compounds that inhibit hsp90 and stimulate hsp70 and hsp40, useful in the prevention or treatment of diseases associated with protein aggregation and amyloid formation |
| JP2004529188A (ja) | 2001-05-23 | 2004-09-24 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | 上昇に関連した癌の治療法 |
| JP4102124B2 (ja) | 2001-08-01 | 2008-06-18 | 富士フイルム株式会社 | ハロゲン化銀乳剤およびハロゲン化銀写真感光材料 |
| WO2003013430A2 (en) | 2001-08-06 | 2003-02-20 | Kosan Biosciences, Inc. | Benzoquinone ansamycins |
| AU2002361345B8 (en) | 2001-11-28 | 2008-06-26 | Ipsen Pharma S.A.S. | 5-sulphanyl-4H-1,2,4-triazole derivatives and their use as medicine |
| AU2002364566B2 (en) | 2001-12-12 | 2009-03-26 | Conforma Therapeutics Corporation | Assays and implements for determining and modulating HSP90 binding activity |
| DE60222804T2 (de) * | 2001-12-21 | 2008-07-03 | Vernalis (Cambridge) Ltd., Abington | 3-(2,4)dihydroxyphenyl-4-phenylpyrazole und deren medizinische verwendung |
| CA2475767A1 (en) | 2002-02-07 | 2003-08-14 | The Curators Of The University Of Missouri | Opioid receptor active 4-(3-hydroxyphenyl) or 4-(3-alkoxyphenyl)-1,2,4-triazole compounds |
| GB0207362D0 (en) | 2002-03-28 | 2002-05-08 | Univ Liverpool | Chemotherapy |
| GB0208516D0 (en) | 2002-04-15 | 2002-05-22 | Univ Liverpool | Chemotherapy |
| GB0228417D0 (en) | 2002-12-05 | 2003-01-08 | Cancer Rec Tech Ltd | Pyrazole compounds |
| GB0229618D0 (en) | 2002-12-19 | 2003-01-22 | Cancer Rec Tech Ltd | Pyrazole compounds |
| US7705027B2 (en) | 2003-02-11 | 2010-04-27 | Vernalis (Cambridge) Limited | Isoxazole compounds as inhibitors of heat shock proteins |
| EP1457499A1 (en) | 2003-03-12 | 2004-09-15 | Tufts University School Of Medicine | Inhibitors of extracellular Hsp90 |
| CA2518836A1 (en) | 2003-03-13 | 2004-09-30 | Conforma Therapeutics Corporation | Drug formulations having long and medium chain triglycerides |
| KR101083621B1 (ko) | 2003-03-17 | 2011-11-16 | 쎄코 툴스 에이비 | 상이한 반경을 지닌 코너부를 가지는 인덱서블 인서트 |
| BR0301799A (pt) | 2003-04-09 | 2005-03-22 | Elzo Ferreira | Uso do processo de extração do extrato, da seiva, da tintura, da massa e dos produtos deles derivados, originários da planta xaxim - dicksonia sellowiana - presl - hooker 1844 pertencente à famìlia das dicksoniaceae para emprego nas seguintes áreas e setores: quìmica humana, industrial, farmacológica, biologia humana e animal, medicinal, fitomedicinal, fitoterápica, alopata, alimentìcia, nutricêutico, vitamìnico, dermatológica, cosmética e veterinária |
| EP1615637A1 (en) | 2003-04-11 | 2006-01-18 | Novo Nordisk A/S | Pharmaceutical use of substituted 1,2,4-triazoles |
| WO2004089415A2 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST |
| WO2004089416A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent |
| SE0301232D0 (sv) | 2003-04-25 | 2003-04-25 | Astrazeneca Ab | Novel use |
| GB0309637D0 (en) | 2003-04-28 | 2003-06-04 | Cancer Rec Tech Ltd | Pyrazole compounds |
| US20050020556A1 (en) | 2003-05-30 | 2005-01-27 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes |
| US20050054625A1 (en) | 2003-05-30 | 2005-03-10 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors |
| US20050020534A1 (en) | 2003-05-30 | 2005-01-27 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites |
| US20050026893A1 (en) | 2003-05-30 | 2005-02-03 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants |
| US20050020557A1 (en) | 2003-05-30 | 2005-01-27 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors |
| US7691838B2 (en) | 2003-05-30 | 2010-04-06 | Kosan Biosciences Incorporated | Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics |
| US20050054589A1 (en) | 2003-05-30 | 2005-03-10 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics |
| GB0315111D0 (en) * | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
| DE602004012578T2 (de) | 2003-08-15 | 2008-12-11 | Vertex Pharmaceuticals Inc., Cambridge | Als inhibitoren von c-met geeignete pyrrolzusammensetzungen |
| JP2005084612A (ja) | 2003-09-11 | 2005-03-31 | Fuji Photo Film Co Ltd | ハロゲン化銀乳剤、ハロゲン化銀感光材料、および熱現像感光材料 |
| JP2007505888A (ja) * | 2003-09-22 | 2007-03-15 | ファイザー インコーポレイテッド | オキシトシン拮抗薬としての置換トリアゾール誘導体 |
| MXPA06003163A (es) | 2003-09-23 | 2006-06-05 | Novartis Ag | Combinacion de un inhibidor de receptor de vegf con un agente quimioterapeutico. |
| AU2004284420A1 (en) | 2003-09-24 | 2005-05-06 | Vertex Pharmaceuticals Incorporated | 4-azole substituted imidazole compositions useful as inhibitors or c-Met receptor tyrosine kinase |
| US20050085531A1 (en) | 2003-10-03 | 2005-04-21 | Hodge Carl N. | Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| JP2007509045A (ja) | 2003-10-18 | 2007-04-12 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 尿失禁および関連疾患の処置用のｇａｂａアゴニストとしての５−置換２−（フェニルメチル）チオ−４−フェニル−４ｈ−１，２，４−トリアゾール誘導体および関連化合物 |
| JP2007509968A (ja) | 2003-10-28 | 2007-04-19 | ファルマシア・コーポレーション | 新形成を治療または予防するためのｈｓｐ９０阻害剤およびホスホジエステラーゼ阻害剤を含む組み合わせ |
| WO2005044194A2 (en) | 2003-10-28 | 2005-05-19 | Pharmacia Corporation | TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR |
| CA2558224A1 (en) * | 2004-03-08 | 2005-09-22 | Wyeth | Ion channel modulators |
| EP1730124A4 (en) * | 2004-03-26 | 2009-04-01 | Amphora Discovery Corp | Certain compounds based on triazole, compositions and applications thereof |
| DE102004039280A1 (de) | 2004-08-13 | 2006-02-23 | Merck Patent Gmbh | 1,5-Diphenyl-pyrazole |
| DE102004049078A1 (de) | 2004-10-08 | 2006-04-13 | Merck Patent Gmbh | Phenylpyrazole |
| KR20140006070A (ko) * | 2004-11-18 | 2014-01-15 | 신타 파마슈티칼스 코프. | Ｈｓｐ90 활성을 조절하는 트리아졸 화합물 |
| DE102005007304A1 (de) | 2005-02-17 | 2006-08-24 | Merck Patent Gmbh | Triazolderivate |
| RU2007137133A (ru) | 2005-03-09 | 2009-04-20 | Ниппон Каяку Кабусики Кайся (Jp) | Новый ингибитор hsp90 |
| JP2008137894A (ja) | 2005-03-22 | 2008-06-19 | Nippon Kayaku Co Ltd | 新規なアセチレン誘導体 |
| US7473784B2 (en) | 2005-08-01 | 2009-01-06 | Bristol-Myers Squibb Company | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors |
| EP1934185A1 (en) | 2005-08-12 | 2008-06-25 | Synta Pharmaceuticals Corporation | Pyrazole compounds that modulate hsp90 activity |
| US8629285B2 (en) | 2005-08-18 | 2014-01-14 | Synta Pharmaceuticals Corp. | Imidazole compounds that modulate HSP90 activity |
| CA2618628C (en) | 2005-08-18 | 2014-11-18 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| CA2653222A1 (en) | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| AU2007267860B2 (en) | 2006-05-25 | 2012-08-09 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate Hsp90 activity |
| CA2653327A1 (en) | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Compounds that modulate hsp90 activity and methods for identifying same |
| US8063083B2 (en) | 2006-05-25 | 2011-11-22 | Synta Pharmaceuticals Corp. | Method for treating non-Hodgkin's lymphoma |
| EP2035396B1 (en) | 2006-05-25 | 2014-05-14 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| CA2653217A1 (en) | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders associated with protooncogene products |
| JP5480623B2 (ja) * | 2006-08-17 | 2014-04-23 | シンタ ファーマシューティカルズ コーポレーション | Ｈｓｐ９０活性を調節するトリアゾール化合物 |
| WO2008051416A2 (en) | 2006-10-19 | 2008-05-02 | Synta Pharmaceuticals Corp. | Compounds that inhibit the activity of hsp90 for treating infections |
| WO2008057246A2 (en) | 2006-10-26 | 2008-05-15 | Synta Pharmaceuticals Corp. | Method for treating inflammatory disorders |
| CA2677481C (en) | 2007-02-08 | 2015-07-07 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| TW200904417A (en) | 2007-02-20 | 2009-02-01 | Synta Pharmaceuticals Corp | Triazole compounds that modulate Hsp90 activity |
| US8993608B2 (en) | 2007-03-12 | 2015-03-31 | Synta Pharmaceuticals Corp. | Method for inhibiting topoisomerase II |
| ES2395114T3 (es) | 2007-03-27 | 2013-02-08 | Synta Pharmaceuticals Corporation | Derivados de triazinona y de diazinona útiles como inhibidores de Hsp90 |
| WO2008153730A2 (en) | 2007-05-25 | 2008-12-18 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders associated with mutations in c-met |
| CN101801983B (zh) | 2007-08-13 | 2014-01-29 | 辛塔制药公司 | 调控hsp90活性的三唑化合物 |
| US8548104B2 (en) * | 2010-11-23 | 2013-10-01 | Siano Mobile Silicon Ltd. | Receiver with configurable clock frequencies |
-
2005
- 2005-11-17 KR KR1020137030848A patent/KR20140006070A/ko not_active Ceased
- 2005-11-17 ES ES10075452.2T patent/ES2594874T3/es not_active Expired - Lifetime
- 2005-11-17 BR BRPI0518315A patent/BRPI0518315B8/pt active IP Right Grant
- 2005-11-17 PL PL05851788T patent/PL1817295T3/pl unknown
- 2005-11-17 HR HRP20130095TT patent/HRP20130095T1/hr unknown
- 2005-11-17 AU AU2005306484A patent/AU2005306484C1/en not_active Ceased
- 2005-11-17 JP JP2007543263A patent/JP4954083B2/ja not_active Expired - Fee Related
- 2005-11-17 EP EP10075452.2A patent/EP2298748B1/en not_active Expired - Lifetime
- 2005-11-17 PT PT58517889T patent/PT1817295E/pt unknown
- 2005-11-17 MX MX2007005940A patent/MX2007005940A/es active IP Right Grant
- 2005-11-17 ES ES05851788T patent/ES2399241T3/es not_active Expired - Lifetime
- 2005-11-17 WO PCT/US2005/041779 patent/WO2006055760A1/en not_active Ceased
- 2005-11-17 US US11/282,119 patent/US7825148B2/en active Active
- 2005-11-17 EP EP10075465.4A patent/EP2295416B1/en not_active Expired - Lifetime
- 2005-11-17 KR KR1020077013728A patent/KR101374553B1/ko not_active Expired - Fee Related
- 2005-11-17 RS RS20130040A patent/RS52642B/sr unknown
- 2005-11-17 NZ NZ555158A patent/NZ555158A/en not_active IP Right Cessation
- 2005-11-17 ME MEP-2013-16A patent/ME01498B/me unknown
- 2005-11-17 EP EP05851788A patent/EP1817295B1/en not_active Expired - Lifetime
- 2005-11-17 CA CA2586612A patent/CA2586612C/en not_active Expired - Lifetime
- 2005-11-17 CN CN2005800418702A patent/CN101072759B/zh not_active Expired - Fee Related
- 2005-11-17 DK DK05851788.9T patent/DK1817295T3/da active
- 2005-11-17 CN CN201310207740.8A patent/CN103554042B/zh not_active Expired - Fee Related
- 2005-11-18 TW TW094140588A patent/TWI380983B/zh not_active IP Right Cessation
-
2007
- 2007-05-10 IL IL183108A patent/IL183108A/en active IP Right Grant
-
2009
- 2009-10-23 US US12/604,970 patent/US9090569B2/en active Active
-
2010
- 2010-06-14 US US12/815,322 patent/US8362055B2/en not_active Expired - Fee Related
-
2012
- 2012-07-16 US US13/550,324 patent/US8901308B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008520702A5 (enExample) | ||
| JP2010500993A5 (enExample) | ||
| JP2009538321A5 (enExample) | ||
| US7767665B2 (en) | 1,3-benzothiazinone derivatives and use thereof | |
| JP2013508378A5 (enExample) | ||
| JP2017505762A5 (enExample) | ||
| JP2009538320A5 (enExample) | ||
| HRP20130095T1 (hr) | Spojevi triazola koji moduliraju aktivnost hsp90 | |
| CA2651363A1 (en) | Triazolopyrazine derivatives useful as anti-cancer agents | |
| JP2009538322A5 (enExample) | ||
| JP2010536753A5 (enExample) | ||
| JP2018520195A5 (enExample) | ||
| JP2006520805A5 (enExample) | ||
| JP2012524111A5 (enExample) | ||
| JP2016164184A5 (enExample) | ||
| JP2010518085A5 (enExample) | ||
| JP2009534386A5 (enExample) | ||
| AU2007267843A1 (en) | Method for treating proliferative disorders associated with protooncogene products | |
| JP2009532464A5 (enExample) | ||
| JP2003502405A5 (enExample) | ||
| JP2003510359A5 (enExample) | ||
| US20130172333A1 (en) | Formulation and dosing of hsp90 inhibitory compounds | |
| JP2007506740A5 (enExample) | ||
| JPWO2021053555A5 (enExample) | ||
| JP2008537930A5 (enExample) |